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Abstract 
 
 
	  iii	  
 
Signal transduction into the cell occurs through cell surface receptors, which specifically 
recognize extracellular messengers and then further transmit the signal to intracellular 
molecules. In the complex system of communication pathways that governs the behaviour 
of the cell, growth factor and cell adhesion signalling tightly and cooperatively cross talk 
to provide crucial stimuli for the regulation of important cellular functions, such as cell 
proliferation, survival and migration. Signalling proteins need to be strictly controlled to 
prevent the rise of pathologies, like cancer and metabolic diseases. In our studies we 
focused on two kinases that belong to different family: Protein Kinase B (PKB) and Focal 
Adhesion Kinase (FAK). They are both key signalling molecules, PKB is activated 
downstream of growth factor-induced PI3K signalling, and FAK downstream of integrin 
cell- matrix adhesion receptors; both have been reported as attractive drug targets. Based 
on a detailed biochemical analysis, we propose a model of how the different PKB domains 
modulate the signalling output. Our results suggest that PKB can follow two distinct 
activation pathways depending on the nature of the upstream signal. Furthermore, we 
propose that PKB targets specific substrates depending on the activation pathway. Such 
new insights on PKB regulation and substrate specificity could allow the interpretation of 
the effects of different classes of PKB inhibitors and enable the design of inhibitors with 
improved specificity. Moreover, we performed a screening of fragments-like compounds 
(<300 Da), interacting with allosteric pockets on the FERM domain of FAK. Crystal 
structures of FERM in complex with these fragments have been solved and structural data 
for two positive fragment hits have been obtained. The collected structural information will 
guide the strategy and design of extended compounds that potentially can be developed 
into allosteric inhibitors.	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Presentación 
	  5	  
Los factores de crecimiento y la señalización de adherencia celular se comunican 
estrechamente para proporcionar el estímulo necesario para la regulación de importantes 
funciones celulares como la proliferación, la supervivencia y la migración. Los factores de 
crecimiento son moléculas importantes para la transmisión de señales desde el exterior de 
la célula hacia su interior. Cuando los receptores transmembrana reciben una señal, la 
transmiten a mensajeros intracelulares. Las integrinas son receptores de adhesión que 
median en la interacción entre los componentes de la matriz extracelular (ECM), 
favoreciendo la transmisión de señales desde el espacio extracelular a la célula, a través de 
proteínas de señalización y proteínas adaptadoras asociadas a las integrinas. Las proteínas 
de señalización necesitan ser estrictamente controladas para impedir la aparición de 
patologías como el cáncer y las enfermedades metabólicas. En este trabajo nos hemos 
centrado en estudio de dos kinasas, pertenecientes a diferentes familias: Proteína Kinasa B 
(PKB) y Kinasa de Adhesión Focal (FAK). Se trata de dos moléculas de señalización 
claves, PKB se activa mediante la vía de señalización inducida por el factor de crecimiento 
PI3K, y FAK mediante la de los receptores de adhesión de integrinas a la matriz celular; 
ambas son atractivas dianas farmacológicas. Basándonos en un detallado análisis 
bioquímico, hemos propuesto un modelo según el cual los diferentes dominios de PKB 
modulan la señalización hacia abajo. Nuestros resultados sugieren que PKB puede seguir 
dos vías diferentes de activación, dependiendo de la naturaleza de la señal hacia arriba. 
Además, proponemos que PKB modula sustratos específicos dependiendo de la vía de 
activación. Esta novedosa información en la regulación de PKB y en su tendencia en 
modular de manera específica sus substratos podría facilitar la interpretación de los efectos 
de las diferentes clases de inhibidores disponibles para PKB y ayudar en el diseño de 
nuevos inhibidores de especificidad mejorada. Además, hemos examinado la interacción 
de compuestos de pequeño tamaño (<300 Dalton) con los bolsillos alostéricos del dominio 
FERM de FAK. Las estructuras cristalinas de FERM en complejo con estos fragmentos 
aportan datos estructurales interesantes para dos de ellos, que nos orientaran hacia la 
estrategia y el diseño de compuestos que podrían ser desarrollados como inhibidores 
alostéricos. 
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1.1 Cell signalling: the communication network of the cell 
 
Mechanisms enabling one cell to influence the behaviour of another have been vital 
already in the world of unicellular organisms as confirmed by studies of present-day 
unicellular eukaryotes such as yeast. In fact, yeast cells communicate with one another for 
mating by secreting a small number of small peptides (Gibeaux R. & Knop M, 2013). In 
contrast, cells in multicellular organisms communicate by means of hundreds of kind of 
signal molecules, including proteins, small peptides, amino acids, nucleotides, steroids, 
retinoids, fatty acid derivatives, and even dissolved gases such as nitric oxide and carbon 
monoxide (Bukoreshtliev N.V et al, 2013). Every aspect of cellular function within a 
multicellular organism, including proliferation, metabolism, gene expression, cytoskeleton 
organisation and cell survival, is dependent on external signalling molecules and it must be 
closely regulated to avoid disorders in these fundamental properties of the cell (Pawson T. 
et al, 2000).  
 
1.1.1 The importance of specificity in signal transduction 
 
The mechanisms by which a wide variety of messages, in form of growth factors, 
hormones and cytokines, are conveyed to their targets in the cytoplasm and nucleus have 
been an object of study over the last four decades. Regardless of the nature of the signal, 
this is a problem of molecular recognition between the signalling molecules and the cell 
surface receptors, specific proteins of the target cells. In fact, extracellular signals bind 
selectively to their membrane receptors, which initiate a characteristic cascade of reactions 
within the cell (Pawson T. et al, 1997). Based on their primary signal transduction 
mechanism, we consider three broad classes of signalling receptors: ligand ion-channel, G-
protein linked receptors (GPLRs) and the protein kinase-linked receptors. The ligand-gated 
ion-channels transiently open or close when activated, resulting in highly selective changes 
in ionic flux (Shupeng L. et al, 2014). GPLRs are non-covalently bound to heterotrimeric 
GTP-binding proteins (G proteins), which mediate the interaction between the receptor and 
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the target protein that can be an enzyme or an ion channel. G proteins act as molecular 
switches by binding GTP (ON state) and then hydrolysing the terminal phosphoester bond 
to leave GDP (OFF state) (Hamm & Gilchrist, 1996). The protein kinase-linked receptors 
are a large family of cell surface receptors and play significant roles in virtually every type 
of cell to promote growth, proliferation, differentiation and survival. The most numerous 
of this type of receptors are the receptor tyrosine kinase (RTK), like the epidermal growth 
factor receptor (EGFR), currently one of the best characterized (Hsuan J.J & Khoon Tan S, 
1997). Upon binding to their ligands, RTK molecules dimerize and undergo 
autophosphorylation on specific tyrosine residues. In turn, they phosphorylate intracellular 
proteins, inducing a cascade of intracellular pathways that trasduce a unique biological 
response, through the interaction of specific cytoplasmic targets (Madhani H D, 2001).  
The propagation of the signal from the cell surface receptors to the cytoplasm and 
nucleus is guarantee by the activation of key intracellular signalling proteins, under a 
highly controlled integration of the signal transduction.  Two major mechanisms of signal 
integration in eukaryotic cells are protein phosphorylation and dephosphorylation, 
mediated by the activity of protein kinases and protein phosphatases. Signal integration can 
be achieved through the phosphorylation of protein that control the levels of second 
messangers, through the phosphorylation of protein kinases and phosphatases themselves 
or through reversible phosphorylation of their substrate (Cohen P, 1992). 
Signal transduction is complicated by the fact that different biochemical pathways 
use the same intracellular effectors to control cellular behaviour. Therefore, an 
evolutionary-suitable way to refine the signalling network was to use modular protein 
domains and recognition motifs, through which specificity is generated during signal 
transduction. (Schlessinger J, 2000). There are different modules that promote specific 
interactions of intracellular signalling proteins and transmembrane receptors with other 
proteins, phospholipids, or nucleic acids. The combination of one or more modular protein 
domains allows variations in binding interfaces to generate new specificities. Examples of 
modules are the Src-Homology 2 domain (SH2), which mediate the docking of 
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intracellular proteins at specific sites in response to tyrosine phosphorylation (Eck et al, 
1993), and the Pleckstrin-Homology domain (PH) that bind charged headgroups of specific 
polyphosphoinositides, promoting the subcellular targeting of signalling proteins to 
specific regions of the plasma membrane (Yoon et al, 1994). 
A molecular understanding of the signalling pathways employed by each type of cell 
surface receptor is therefore essential to learn about many cellular functions and, 
consequently, to treat efficiently diseases caused by breakdowns in the signalling process, 
by targeting specifically the malfunctioning signalling molecules (Hsuan J.J & Khoon Tan 
S, 1997).  
 
1.2 Growth and Adhesion signalling  
 
In the intricate network of signalling pathways inside the cell, we focused our 
interest on growth factor and cell adhesion induced-signals, which both provide crucial 
stimuli for cell proliferation, survival and migration. As already mentioned, growth factors 
are important molecules for signal transduction into the cell through transmembrane 
receptors, like the RTK, that then further mediate the signal via intracellular messengers. 
On the other hand, at the level of the focal adhesion, point of contact between the cell 
surface and extracellular matrix (ECM) components, the integrin family of adhesion 
receptors mediate the intracellular signal propagation of the extracellular cues. (Ridley et 
al, 2003). Integrins are heterodimeric cell-surface molecules that on one side link the actin 
cytoskeleton to the cell membrane and on the other side mediate cell-matrix interactions. In 
addition to their structural function, they mediate signalling from the extracellular space 
into the cell through integrin-associated signalling and adaptors like FAK, ILK and PINCH 
(Hanningan GE, et al, 1996). Via these molecules, integrin signalling tightly and 
cooperatively interacts with RTK signalling to regulate cell survival, proliferation, cell 
shape as well as polarity, adhesion migration and differentiation, and therefore needs to be 
strictly controlled. In fact, their deregulation leads to different pathologies like cancer and 
metabolic diseases (e.g. diabetes). Consequently, proteins associated to all the major signal 
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transduction pathways downstream these receptors are likely good drug target candidates 
in therapeutic approaches (Megison M.L et al, 2013). In the complex scenario of the cell-
signalling transduction, we focus our interest on two protein kinases that belong to 
different families: Protein Kinase B (PKB) and Focal Adhesion Kinase (FAK). They are 
crucial effectors downstream growth factor receptors and integrin cell- matrix adhesion 
receptors respectively and they are both interesting drug target, since they are both protein 
kinases and they crucial regulator of fundamental cellular processes (Fig. 1.1). 
 
 
Fig.1.1- Schematic representation of the growth factor and adhesion signalling pathways. Cooperative 
integrin-RTK signalling determines survival, proliferation, differentiation and apoptosis of cell by a cascade 
of downstream signals. Kinase activity of PI3K is Ras-dependent and leads to the activation of PKB 
parthway by increasing the intracellular concentration of PIP3. Upon cell attachment via integrins to the 
ECM, FAK is localised to focal adhesions through binding to paxillin, linking integrin receptors to 
intracellular signalling pathways. Furthermore FAK plays a role in connecting the integrins and growth 
factors receptors pathways. 
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1.3 Protein kinases in cell signalling 
 
 
Protein phosphorylation is one of the major mechanisms of signal integration in 
eukaryotic cells and consists in transfer phosphate groups from donor molecules at high 
energy, like ATP and its derivatives. The phosphorylation of a substrate can inhibits its 
activity or allow its binding to other proteins, carrying domain which recognized 
phosphorylates residue of Ser, Thr and Tyr. In fact, phosphorylation of Ser, Thr and Tyr 
residues can trigger conformational changes in regulated proteins, which alter their 
properties and start a controlled physiological response (Adams JA & Taylor SS, 1995) 
Phosphorylation process is achieved by the activity of a specific family of enzymes, 
the protein kinases, also known as phosphotrasferase. All kinases require a metal ion, like 
Mg2+ or Mn2+ in order to stabilize the high-energy bonds of the ATP, the donor molecule, 
and allow the phosphorylation reaction (Bossemeyer D. et al, 1993).  
These proteins are classified in tyrosine, serine or threonine kinases, according to the 
substrate amino acid residue that is phosphorylated. As already mentioned, the spatial and 
temporal control of phosphorylation events is crucial to many cellular processes, including 
metabolism, transcription, cell cycle progression, cytoskeleton rearrangement, cellular 
movement, apoptosis and cell differentiation. Therefore, protein kinases play an important 
role in cell function and maintenance and this control relies on the proper regulation of 
protein kinases. Consequently, kinase activity in the wrong place or at the wrong time can 
lead to cell transformation and the rise of pathologies, such as cancer and diabetes (Rubin 
G M, et al, 2000). 
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 1.3.1 The Kinome 
  
Protein kinases represent the largest group of enzyme in nature. In fact, the human 
genome codes about 520 protein kinase genes (Hunter T, 1987). Although most of these 
genes are well characterized, a large number of genes code for proteins recognized more 
recently as kinases only after computational analysis. The part of the human genome that 
codes for protein kinases is commonly defined as the “kinome”. The kinome is in 
continuous expansion, both for the discovery of additional genes and for potential protein 
variants, translated after splicing events (Milanesi L. et al, 2005). There are often several 
kinases able to phosphorylate the same substrate. Most protein kinases act in a network of 
kinase and other signal effectors of different nature, as their activity is modulated by 
autophosphorylation and phosphorylation by other kinases. (Reviewed in Manning G. et 
al, 2002). Protein kinases mutations and misregulation play a fundamental role in human 
pathogenesis, and their structural organisation and characteristics make them good targets 
in clinical therapies (Blume-Jensen P. & Hunter T, 2001). 
 
1.3.2 Protein kinase structure and activity 
 
Protein kinases show an extremely well conserved structural organisation among 
serine/threonine and tyrosine kinases, although they display high substrate specificity. In 
the structure of these enzymes (Fig. 1.2), we can recognize two lobes or subdomains. The 
smaller N-terminal lobe consists of a 5- stranded β sheet and one prominent α helix, called 
helix αC. On the other hand, the C-terminal lobe (C lobe) is larger and predominantly 
helical (Zheng et al, 1993). ATP is bound in a deep cleft between the two lobes and sits 
beneath a highly conserved loop for phosphate binding, the P loop (in yellow in Fig 1.2), 
connecting strands β1 and β2 (Johnson L N et al, 1998). The P loop contains a conserved 
glycine-rich sequence motif GXGXφG, where φ is usually tyrosine or phenylalanine. The 
glycine residues allow the loop to approach the phosphates of ATP very closely and to 
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coordinate them via backbone interactions, thanks to their low steric hindrance 
(Mohammadi et al., 1997). The glycine residues make the P loop very flexible in the 
absence of ATP, a fact that facilitates the binding of small molecule inhibitors. Some of 
these inhibitors induce large structural distortions in the loop by interacting with the 
conserved aromatic residue (Schindler et al., 2000).  
 
 
Fig.1.2- Casein Kinase 1δ  (PDB code: 1CKI). Key structural elements conserved in protein kinases are 
highlighted. Activation loop in red, helix αC in blue, P loop in yellow, catalytic loop in green. In the zoom 
insert the binding pocket in complex with the ATP nucleotide and some highly conserved residues in the 
active site are shown. In anticlockwise there are: Gly156 of the DFG motif at the end of the activation loop; 
Glu55 of the helix αC; Lys41 of the N-terminal lobe; Asn136 which coordinates ATP and Mg2+; Asp131 and 
Arg130 of the conserved HRD in the catalytic loop, where the arginine helps to coordinate ATP phosphate 
groups.  
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In the binding pocket, ATP interacts through the adenine ring, establishing hydrogen 
bonds with the kinase hinge, the connecting loop between the N- and the C-terminal lobe. 
Instead, the ATP ribose and triphosphate groups bind in a hydrophilic channel towards the 
binding site for the substrate, which is characterized of conserved aminoacids, essential for 
catalysis (review in Zhang J. et al, 2009).  The correct transfer of the phosphate required a 
precise spatial disposition of some catalytic residues, conserved in all kinases (review in 
Huse M & Kuriyan J, 2002). Among them, there are an aspartate residue and an asparagine 
within the catalytic loop, a conserved structure at the bottom of the active site (Fig 1.2). 
The aspartate interacts with the substrate binding hydroxyl side chain, whereas the 
asparagine is involved in hydrogen bonds, which orient the above-mentioned aspartate  
(Hubbard et al, 1994). This asparagine residue is also required, together with another 
conserved residue of aspartate, for the binding with two bivalent cations (usually Mg2+), 
involved in the recognition of the nucleotide. In the N lobe, there is a lysine residue, 
fundamental to place correctly the phosphate α and β groups during the catalysis. The 
lysine is buried in the cleft between the two lobes where it is itself stabilized and correctly 
oriented by ionic interactions with a glutamate residue of the helix αC (see insert in Fig 
1.2). The peptide substrate binds in an extended conformation across the front end of the 
nucleotide-binding pocket, close to the γ-phosphate of ATP. All kinases have a centrally 
located and conserved loop, known as “activation loop”, typically 20-30 residues in length 
(Fig1.2). It is an important element in kinase activity regulation and it is characterized by 
DFG and APE motif, respectively located at the beginning and at the end of the activation 
loop (reviewed in Zhang J. et al, 2009). The DFG motif structure, in particular the aspartic 
acid residue conformation, is closely connected to the phosphorylation of the activation 
loop, which stabilizes the loop itself in a open and extended conformation that allows the 
substrate binding (reviewed in Huse M et al, 2002). The localisation and the total number 
of the phosphorylation sites in the activation loop changes from kinase to kinase (Russo A 
A et al, 1996). Whereas the phosphorylated activation loop conformation is conserved, it 
can undertake a wide range of conformations in the unphosphorylated state. Protein 
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kinases are molecular switches that can adopt at least two extreme conformations: an “on” 
state that is maximally active, catalytically competent, where the activation loop is 
generally phosphorylated (Hubbard, 1997), and a “off’ state, where the activation loop is 
not positioned for optimal substrate binding (Hubbard et al, 1994) (Fig. 1.3). An important 
element of the conformational changes in the catalytic site is the helix αC. This helix helps 
the formation of direct contacts between the activation loop and the N lobe, and its 
conformation is often DFG motif-dependent (Jeffrey et al, 1995- Xu et al, 1997). 
 
 
Fig.1.3- Active and Inactive conformations of the Protein Kinase Domain. The three structures 
schematize the conformational transitions involved in the regulation of kinase activity, with particular 
emphasis on the C helix and activation loop. The catalytic lysine and glutamate (Lys72 and Glu91 in PKA), 
which form a salt bridge in active kinase conformations, are shown in each schematic (adapted from Huse M. 
et al, 2002) 
1.3.3 Protein kinase inhibitors 
The ability of the protein kinase activation loop to adopt different conformational 
states when the enzyme is in a “off’ state, has been recently used for important clinical 
benefits. Antitumoral drugs that target kinases, like Gleevec, are all small molecules able 
to bind to different kinase sites, either in the active or inactive conformation (Cohen P. 
2002). The majority of the so far discovered inhibitors compete for the ATP binding and 
show from one to three hydrogen bonds with the amino acids residues in the hinge loop of 
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the target enzyme. In this way, the hydrogen bonds usually formed by the ATP adenine 
ring are mimicked (Traxler P et al, 1999). According to the inhibition mechanism 
followed, protein kinase inhibitors can be classified in: type I inhibitors, type II inhibitors, 
covalent inhibitors and allosteric inhibitors. 
Type I inhibitors- This type of inhibitors targets the ATP binding site in an active 
conformation of the kinase (Liu Y, 2006). They typically consist of a heterocyclic ring 
system. In active kinases, when the purine binding site assumes a “DFG-in” conformation, 
these inhibitors occupy the binding site at the level of the binding pocket hydrophobic 
regions, mimicking the ATP molecule (Fig. 1.4). By blocking the ATP binding, the 
activity of the enzyme is prevented (reviewed in Zhang J. et al, 2009). 
 
Fig.1.4- Representation of the kinase inhibition mechanism in presence of type I inhibitors. The 
activation loop takes a “DFG-in” conformation, in presence of PD166326 inhibitor bound to ABL1 (PDB 
code: 1OPK). 
 
 
Type II inhibitors- In this case, the inhibitors target an inactive conformation of the 
ATP binding site, known as “DFG-out” state, where the Asp side chain points out of the 
active site and the Phe blocks the access of ATP to the active site. Movement of the 
activation loop to the “DFG-out” conformation exposes an additional hydrophobic back-
pocket, directly adjacent to the ATP binding site (Fig. 1.5). These compounds inhibit 
protein kinases, preventing ATP binding and stabilizing the inactive conformation of the 
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protein. Examples are Gleevec, Nilotinib (Manley P.W. et al, 2005), and Sorafenib (Wan 
P.T et al, 2004), inhibitors of ABL1, KIT, Ras and PDGFR. 
 
 
 
Fig.1.5- Representation of the kinase inhibition mechanism in presence of type II inhibitors. The 
activation looptakes a “DFG-out” conformation, in presence of Gleevec bound to ABL1 (PDB code: 1IEP). 
 
Covalent inhibitors- This type of inhibitors formsa covalent bond with the protein 
target, usually via cys sidechains, To date, inhibitors developed of this type occupy the 
ATP binding pocket like type I ones (Fig. 1.6). Covalently likned inhibitors block the 
ATP- kinase binding in an irreversible way, keeping the enzyme inactive (Cohen M.S. et 
al, 2005). Examples are the inhibitors 34-JAB, HKI-272 and CL-387785, specific for the 
Epidermal Growth Factor receptor (EGFR) (Fry D.W et al, 1994). 
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Fig.1.6- Representation of the kinase inhibition mechanism in presence of covalent inhibitors. The 
activation loop adopts a “DFG-in” conformation, in presence of the 6-acrylamide group of 34-JAB inhibitor 
in the active site of the epidermal growth factor receptor (PDB code: 2J5F). 
Allosteric inhibitors- They bound outside the ATP binding site and modulate kinase 
activity in an allosteric manner (Fig 1.7). The best-characterized members of this class of 
inhibitors are CI- 1040 and PD334581, that inhibit MEK1 and MEK2 (Ohren J et al, 
2004). Other examples are GNF2, Akti-1 and BMS-345541, respectively specific for BCR-
ABL1, PKB and nuclear factor kB kinase (Adrian F.J et al, 2006 - Lindsley C.W et al, 
2005- Mclntyre KW et al, 2003). Inhibitors that belong to this category tend to exhibit the 
highest degree of kinase selectivity because they exploit binding sites and regulatory 
mechanisms that are unique to a particular kinase. Allosteric inhibitors can bind far away 
from the ATP binding site or can occupy the ATP binding backpocket, if the DFG motif 
adopts an “out” conformation (reviewed in Zhang J. et al, 2009). 
 
Fig.1.7- Representation of the kinase inhibition mechanism in presence of allosteric inhibitors. The 
activation loop undertakes a DFG  “out” conformation, in presence of PD334581, bound to MEK2 (PDB 
code: 1S9I). 
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1.4 Protein Kinase B (PKB) 
 
Protein Kinase B (PKB), also known as Akt, is a member of the serine/threonine 
AGC protein kinase family. Three highly homologous isoforms of PKB exist in mammals 
(PKB-α/Akt1, PKB-β/Akt2 and PKB-γ/Akt3), each of them containing an amino (N)-
terminal pleckstrin homology (PH) domain, a kinase domain and a 21-amino acid carboxy 
(C)-terminal hydrophobic motif (HM) (Fig. 1.8). These three isoforms mainly differs on 
the tissue distribution. PKBα is widely distributed and is implicated in cell growth and 
survival (Chen W.S. et al, 2001), whereas PKBβ is highly expressed in muscle and 
adipocytes and contributes to insulin-mediated regulation of the glucose homeostasis 
(Garofalo et al, 2003). PKBγ, instead, is more restricted with expression mainly found in 
the testes and brain (Tschopp et al, 2005). PKB is a key-signalling molecule downstream 
of growth factor induced phosphoinositide 3-kinase (PI3K) signalling. Many growth 
factors and cytokines stimulate an increase in activity in the lipid enzyme PI3K, resulting 
in a subsequent increase in phosphatidylinositol 3,4 bisphosphate (PIP2) and 
phosphatidylinositol 3,4,5 trisphosphate (PIP3) in the cell (Bellacosa A. et al, 1998) 
Previous work has revealed that the 3-phosphoinositides interact with the PH domain of 
PKB, recruiting the kinase to the inner surface of the plasma membrane. Upon binding of 
PIP3, PKB undergoes a conformational change where the PH domain changes the position 
relative to the kinase domain (Toker A & Newton A C, 2000). It has been shown that 
phosphoinositide-dependent kinase 1 (PDK1) directly activate PKB by phosphorylating 
T308 (PKBα numbering) in the activation loop (Alessi D. et al, 1997). To achieve full 
kinase activity, PKB needs to be phosphorylated at a second key residue, S473, which is 
located in the HM region. S473 is phoshorylated by members of the PI3K-releted kinase 
family, mTORC2 or DNA-PK, depending on the stimulus and the context (Sarbassov DD. 
et al, 2004). The contribution of Ser473 phosphorylation in the regulation of Thr308 
phosphorylation, Akt activity and phosphorylation of downstream substrates is not yet 
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fully understood. Initial studies using alanine mutants showed that Akt Thr308 and Ser473 
could be phosphorylated independently of each other (Alessi et al, 1996a). 
 
 
Fig.1.8- Domain structure of PKBβ  isoform. A) PKBβ comprises three functional domains: an N-terminal 
PH domain, a central kinase domain, and a C-terminal hydrophobic motif (HM). The domain structure shown 
is highly conserved also in PKBα and PKBγ isoforms. B) Crystal structures available in literature for PKB 
are shown, adapted from Thomas C.C et al, 2002 (PDB code: 1H10), Yang J. et al, 2002a (PDB code: 
1GZO), Yang J. et al, 2002b (PDB code: 1O6L) and Wu W. et al, 2010 (PDB code: 3O96). 
1.4.1 PKB substrates  
 
Upon Akt phosphorylation and activation, PKB dissociates from the membrane and 
translocates to the cytosol and nucleus,	  where it activates downstream signalling pathways 
through phosphorylation of a huge variety of substrates (reviewed in Hers I et al, 2011). In 
the large list of PKB cytoplasmic and nuclear targets, we include Bcl-2-associated death 
promoter (BAD), Forkhead box transcription factor class O (FOXO), Tuberous sclerosis 
complex 2 tumor suppressor (TSC2), Glycogen synthase kinase-3 (GSK3), and protein 27 
(p27), also called Kip1. Phosphorylation by PKB can have various effects on protein 
substrates, including inhibiting or stimulating theirs activities, altering their subcellular 
localisation, protecting them against degradation or regulating binding to protein partners 
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(reviewed in Manning & Cantley, 2007). Within the different PKB targets, some can 
directly be related to specific cellular responses, even thought each physiological response 
downstream of PKB appears to be mediated by multiple targets (Fig. 1.9). For example, 
PKB promotes cell survival by blocking the function of proapoptotic proteins, such as 
BAD, and preventing the FOXO-mediated transcription of target genes that promote 
apoptosis and cell-cycle arrest (Brunet A, et al 2009). Furthermore, one of the best-
conserved functions of PKB is its role in promoting cell growth through the 
phosphorylation-driven inhibition of TSC2, a critical negative regulator of mTORC1 
signalling (Inoki K et al, 2002). Moreover, p27 phosphorylation by PKB prevents its 
nuclear localisation promoting cell proliferation (Liang J et al, 2002), whereas GSK3 
phosphorylation inhibits GSK3, a regulatory kinase of Glycogen synthase (GS) (Cross et 
al, 1995).  
PKB is, therefore, an important and versatile protein kinase at the core of the human 
physiology, due to its function in the regulation of important cellular processes, like the 
ones listed above. Aberrant regulation of the PKB pathway is implicated in the 
pathogenesis of different diseases, including several human cancers (Roy H.K et al, 2002), 
type-2 diabetes (Cho H et al, 2001) and cardiovascular and neurological diseases (Shiojima 
I et al, 2002- Datta S et al, 1997). Hence, PKB is therefore considered an important drug 
target and several small molecule inhibitors of PKB have been developed to date.  In fact, 
different sites on the PKB provide functionally important regions suitable for binding 
ATP-competitive, allosteric, substrate competitive inhibitors as well as inhibitors of PIP3 
binding, but most of them are lacking sufficient selectivity (reviewed Lindsley et al, 2010). 
Although, the mechanism by which PKB is activated has heavily been studied using 
cell biology experiments, there are still open questions, mainly about how mechanistically 
all the regulatory mechanisms act together to control PKB activity, membrane association, 
release upon full activation and how the regulatory elements of PKB can lead to substrate 
specificity. Therefore, new insight on PKB regulation and structure could allow the 
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interpretation of the effects of different classes of PKB inhibitors and enable the design of 
inhibitors with improved selectivity.  
 
 
 
Fig.1.9- Downstream PKB effectors. PKB phosphorylation leads to the activation or inhibition of many 
downstream effectors. Their regulation by PKB contributes to the cellular processes and effects indicated. 
The deregulation of PKB downstream effectors phosphorylation may lead to diseases such as diabetes, 
cancer and cardiovascular/ hearth disease (adapted from Hers I. et al, 2011). 
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1.5 Focal Adhesion Kinase (FAK)  
 
Focal Adhesion Kinase is a non-receptor tyrosine kinase (NRTK) that is localized at 
focal adhesion, the contact sites between cells and extracellular matrix (Ridley et al, 2003). 
FAK protein structure includes an amino (N)-terminal FERM (4.1, ezrin, radixin, moesin 
homology) domain, a ≈ 40 residue linker region, a central kinase domain, a ∼ 220 proline-
rich low complexity region, that interacts with other signalling molecules and a carboxyl 
(C)- terminal FAT (focal adhesion targeting) domain (Fig.1.10). The FERM domain is 
responsible for regulating the catalytic activity of FAK. It consists of a three-lobed protein 
interaction domain (F1, F2 and F3 lobes), arranged in a “clover leaf” structure. The F1 
lobe adopts an ubiquitin-like fold, the F2 resembles acyl CoA binding protein and the F3 
lobe exhibits the pleckstrin homology (PH) or phosphotyrosine binding (PTB) domain fold 
(Ceccarelli et al, 2006). On the other hand, the FAT domain consists of a four-helix bundle 
and is critical for targeting FAK to focal adhesions via binding to paxillin, but it is not 
thought to play a direct role in catalytic regulation of FAK (Hayashi I et al, 2002). 
In the autoinhibited state, the FERM domain binds directly to the kinase C-lobe, 
impeding access to the active site and protecting FAK’s activation loop from 
phosphorylation by Src (Cooper et al, 2003). When the FERM domain is released, FAK 
Tyr397 in the linker region becomes autophosphorylated, leading to exposure of a docking 
site for the SH2 domain of the Src kinase (Jacamo et al, 2005). The interaction between 
Tyr397-phosphorylated FAK and Src leads to a cascade of tyrosine phosphorylation of 
multiple sites on FAK by Src (Y576, Y577, Y925), as well as binding of other signalling 
molecules, such as p130Cas and paxillin, resulting in cytoskeletal changes and activation 
of other downstream signalling pathways (Lietha D, et al, 2007). 
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Fig.1.10- Domain structure of Focal Adhesion Kinase. A) FAK consists of a N-terminal FERM (blue), a 
central kinase (red) and a C-terminal FAT (focal adhesion targeting) domain (brown). B) Ribbon 
representation of the FERM-Kinase crystal structure adapted from Lietha D. et al, 2007 (PDB code: 2J0J) 
and of the FAT domain structure adapted from Hayashi I. et al, 2002 (PDB code: 1K40). 
 
FAK becomes tyrosine phosphorylated in response to a number of stimuli, such as 
mitogen agents, integrin clustering or growth factor receptor signalling (Schaller MD et al, 
2001). In turn, FAK is involved in the regulation of multiple cellular functions, such as 
proliferation, survival, invasion, metastasis, adhesion and angiogenesis (Schlaepfer DD et 
al, 1999). Indeed, FAK is frequently overexpressed in many types of tumours, including 
those of skin, brain, colon, breast, liver and thyroid, and it is highly correlated to invasive 
phenotypes in these tumours (Bonome T et al, 2005). Therefore, FAK is represents an 
important target for the development of anti- neoplastic and anti-metastatic drugs (Halder J 
et al, 2007). We previously discussed that several kinase inhibitors of different classes are 
currently in clinical use for the treatment of cancer and other diseases. Previous studies 
showed TAE226, a bis-anilino pyrimidine compound, as a potent ATP- competitive 
inhibitor of FAK (IC50= 5.5nM), but it also inhibits both insulin receptor (44nM) and 
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insulin-like growth factor I receptor (IC50 = 140nM), even though less potently (Liu TJ et 
al, 2007).  
Since FAK is structurally and functionally well characterized, it is a suitable target to 
design more selective inhibitors, for example by developing inhibitors that target FAK 
allosterically. 
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Objectives 
 
In this thesis the following objectives have been pursued: 
 
1. Understand the regulatory mechanism of Protein Kinase B (PKB) at atomic level  
and, in particular, biochemically and structurally investigate:  
a) the mode of PKB autoinhibition in its basal state; 
b) how the binding to PIP3 and phosphorylation of the activation loop and of the 
hydrophobic motif affect the catalytic activity, accessibility of phosphorylation sites, 
PIP3 binding and substrate specificity.  
 
2. Utilize the structural information and the mechanistic insight available for FAK to 
identify allosteric Focal Adhesion Kinase (FAK) modulators targeting the regulatory 
FERM domain of FAK.  
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Objetivos 
 
Los objetivos que se pretenden conseguir con esta tesis son: 
 
1. Entender el mecanismo regulador de la Proteína Kinasa B a nivel atómico y, en 
particular, investigar a nivel bioquímico y estructural:  
a) el modo de autoinhibición de PKB en su estado basal;  
b) cómo la interacción con PIP3 y la fosforilación del loop de activación y del motivo 
hidrofóbico (HM) afectan la actividad catalítica, la accesibilidad de sitios de 
fosforilación, la interacción con PIP3 y la especificidad de sustratos. 
 
2. Identificar moduladores alostéricos de la Kinasa de Adhesión Focal (FAK) 
dirigidos al dominio regulador FERM de FAK, basándose en la información 
estructural disponible. 	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3.1 Media, buffers and antibiotics 
 
- LB (Luria-Bertani): 10g/L Casein pepton, 5g/L yeast exctract, 5g/L NaCl 
- TAE (1X): 40mM Tris-acetate, 1mM EDTA 
- Laemmli loading buffer (5X): 200mM Tris pH 6.8, 4% SDS, 20% Glycerol, 10% β- 
mercaptoethanol, 0.04% bromophenol blue 
- SDS-PAGE stacking gel: 5% acrylamide, Stacking buffer pH 6.8 (125mM Tris HCl pH 
6.8, 0.1% SDS), 0.1% APS, 0.1 % TEMED 
- SDS-PAGE resolving gel: variable % acrylamide (8-15%), Resolving buffer pH 8.8 
(378mM Tris HCl pH 8.8, 0.1% SDS), 0.1% APS, 0.1 % TEMED 
- Running buffer for SDS-PAGE electrophoresis (1X): 192mM Glycin, 25mM Tris-HCl 
pH 6.8, 1% SDS 
- Coomassie solution: 2g/L Coomassie Brilliant-blue, 10% Ethanol, 40% Acetic acid 
- Destaining solution: 10% Ethanol, 40% Acetic acid 
- TBS (1X): 150mM NaCl, 20mM Tris HCl pH 7.6 
- TBS-Tween (TBST): 150mM NaCl, 20mM Tris HCl, 0.05% Tween (v/v), pH 7.6 
- PBS (1X): 150mM NaCl, 3mM KCl, 10mM Na2HPO4, 2mM KH2PO4, pH 7.6 
- PBS-Tween (PBST): 150mM NaCl, 3mM KCl, 10mM Na2HPO4, 2mM KH2PO4, 0.05% 
Tween (v/v), pH 7.6 
- ELISA binding solution: 30mM Na2CO3, 70mM NaHCO3, pH 9.6 
- ELISA stop solution: 180 mM H2SO4, water 
- Antibiotics: 100mg/ml Ampicillin, 30mg/ml Kanamicin, 33 mg/ml Chloramphenicol  
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3.2 Plasmid vectors 
 
pET HisTT: modified version of T7lac promoter vector pET 32 (Novagen), that adds 
an N-terminal 6xHis tag, a TEV cleavage site and a thrombin site to the proteins expressed 
in bacteria. The expressed protein is fused to the His tag to allow the purification of the 
protein from the bacterial lysate. Downstream the 6xHis sequence, there are a cleavage site 
for the Thrombin and for the TEV protease in order to remove the affinity TAG. The 
plasmid carries a Kanamicin resistence. This plasmid has been used to over-express most 
of the human Protein Kinase B (PKB) constructs and PDK1 Kinase. Dr. Brian Hemmings 
at the Friedrich Miescher Institute (FMI) in Basel (Switzerland) gently provided the 
original pFastBac vectors containing the codifying sequences for PKB (Homo sapiens) and 
PDK1 (Homo sapiens). The restriction enzyme sites used for cloning are shown in Tab 3.1. 
pET GST: modified version of pET 32 (Novagen) as described in pET HisTT, but in 
this case, an N-terminal GST tag is added to the proteins expressed in bacteria to allow the 
purification of the protein from the bacterial lysate. This plasmid has been used to over-
express FAK 31-405 wt. The codifying sequence for FAK (Gallus gallus) was previously 
cloned from a pBluescript vector in Mike Eck's laboratory (Dana-Faber Cancer Institute) 
and gently provided. The restriction enzyme sites used for cloning are shown in Tab 3.1. 
pOPIN-F: modified version of three-promoter vector pTriEx2 (Novagen), that allows 
the expression of recombinant proteins in E.coli, mammalian and insect hosts. This vector 
has been constructed based on the In-FusionTM cloning enzyme, which allow a ligation-
independent cloning (Berrow et al, 2007). This plasmid includes a N-terminal 6xHis fusion 
tag and it contains a Prescission cleavage site, downstream the 6xHis sequence, to remove 
the affinity tag. The plasmid carries an Ampicillin resistance. This plasmid has been used 
to over-express PKB Kinase+HM S474D and zebrafish PKB FL wt. The original pFastBac 
vectors containing the codifying sequence for PKB (Homo sapiens) was gently provided 
by Dr. Brian Hemmings (FMI-Basel-CH), whereas cDNA PKB (Danio rerio) was bought 
from Source BioScience.  
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Tab. 3.1- Primers list. Primers used to amplify PKB, PDK1 and FAK constructs and to clone them in the A) 
pET family vectors and in the B) pOPIN-F. In bold we highlight A) the nucleotides of the restriction cutting 
site sequence for the corresponding restriction enzyme and B) the primer extension peculiar of the pOPIN 
vectors (Berrow et al, 2007). Tm= melting temperature of the primers. The melting temperature is calculated 
based on the length of the DNA and the GC ratio [Tm = 71 + 0.41*(%GC) – 675/length]. 
 
3.3 E.coli strains 
XL1-Blue: chemically competent host strain of E.coli suitable for routine cloning 
applications of plasmid or lambda vectors. This strain allows blue-white colour screening 
for recombinant plasmids.  
BL21 (DE3): chemically competent host strain of E.coli suitable for transformation and 
protein expression. 
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BL21 (DE3)-pLysS: chemically competent host strain of E.coli, containing the pLys S 
plasmid which allow a tighter control of protein expression and is Chloramphenicol 
resistant. This host strain is therefore ideal for transformation and expression of proteins 
that are toxic to E.coli and/or exhibit high leakage of expression under uninduced 
condition, due to high copy numbers, as is the case for pOPIN vectors. 
3.4 Cloning 
 
To amplify the coding sequence of interest we use the polymerase chain reaction 
(PCR), performed in a thermocycler. The cycles of reaction are divided in three steps: 
initial denaturation step (2 min/ 95°C)/ 1 cycle; denaturation (30sec /95°C), primer 
annealing (45sec/ TA, where TA= Tm- 4°C), and extending phase (1 min/kb/ 72°C) form the 
second step (30cycles); final extending step (10 min/ 72°C). The 50ul of the reaction 
mixture contain: 100ng DNA template, 0.4uM primer 5’, 0.4uM primer 3’ (Tab. 3.1), 
200uM dNTPs, Pfu Ultra High Fidelity DNA Polymerase (2.5U/ reaction) and the reaction 
buffer (10X Pfu Ultra HF buffer). Run an electrophoresis on a 1% agarose TAE 1X gel at 
90V to check that the size of the amplified sequence is corrected. In the case of ligation-
dependent cloning (see 3.4.1), clean the reactions to remove salts in excess using 
“QIAGEN PCR purification” kit according to the manufacturer protocol.  
 
3.4.1 Ligation-dependent cloning 
 
Both the fragment of interest and the host plasmid vector need to be digested with 
the chosen restriction enzymes (Tab. 3.1), in presence of BSA and the specific buffer that 
guarantee a high level of cutting efficiency for both restriction enzymes. Incubate the 
reactions at least 3 hours at 37°C (max 16 hours). Digested DNA fragments are separated 
on a 1% agarose TAE 1X gel at 90V. Locate bands and slice the gel with a scalpel. DNA is 
then extracted and purified using “Gel Extraction kit” (QIAGEN) according to the 
manufacturer protocol. The digested amplified DNA sequences and the digested vectors 
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are covalently linked in presence of a DNA ligase. The 15ul ligation mixture contains the 
following: ~100ng of digested plasmid vector, DNA insert (4X molar concentration of 
vector), T4 DNA ligase 10X buffer (New England BioLabs), 1ul of T4 DNA ligase (New 
England BioLabs) and water. Incubate the mixture at 16°C for 16 hours. 
 
 
3.4.2 In-Fusion®  ligation-independent cloning (Clontech) 
 
To transform In-Fusion® reaction, the pOPIN-F need to be previously linearized 
using restriction enzymes (KpnI/HindIII) according to the manufacturer protocol of In-
Fusion® HD cloning kit (Clontech). Treat unpurified PCR fragments with Cloning 
Enhancer (Clontech) and, then, follow the In-Fusion Cloning procedure for Cloning 
Enhancer-treated PCR fragments as described in the manufacturer protocol. 
 
 
3.5 Transformation of competent cells 
To transform chemically competent cells directly incubate 2.5-5ul of cloning DNA 
products with 50ul aliquot of XL1-Blue cells on ice for 10 min. Then, heat shock cells at 
42°C for 45 sec without agitation and transfer directly the competent cells on ice and 
incubate for 30 min. So-transformed cells are then let grown in 300ul of LB and incubate 
at 37°C for 1h. Streak the cells on plates containing LB agar and the antibiotic of selection 
(see 3.1 for final concentration used). Incubate the plates overnight at 37°C.  
3.6 Prep of plasmid DNA from E.coli 
After transformation of 50ul of E.coli competent cells with 50ng of DNA to amplify 
the vectors after ligation, pick a single colony from the plate. Inoculate it in 5ml of LB and 
the antibiotic of selection and let it shake at 37°C for 16 hours. Afterwards, centrifuge the 
cells at 3300xg for 15 min, removing the supernatant and keeping the pellet. To isolate the 
plasmid DNA we follow the manufacturer protocol of the “QIAprep ® Spin Miniprep” kit. 
Elute the plasmid DNA in 30ul of water after 15min incubation and keep it at -20°C. 
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3.7 Clone sequencing 
The DNA sequencing of the obtained clones is performed by the internal facility of 
the Spanish National Cancer Research Centre (CNIO). Confirmed clones are then used for 
protein expression. 
3.8 Expression of recombinant proteins in E.coli  
Expression constructs are transformed in E.coli (BL21 or BL21-pLysS) following 
the heat shock protocol and then streak the cells on plates containing LB agar and the 
antibiotic/s of selection. For all the constructs, prepare 2x50 ml of LB media with the 
antibiotic/s of selection. Inoculate a colony and let the cells growing in a shaker at 37°C for 
16 hours. From this point the protocol of expression has to be optimized in a construct-
dependent manner in order to improve the level of expression of soluble proteins. 
1) PKB PH domain: dilute the cells grown overnights in 1 L of LB media in order to 
have a starting optical density (OD600) ∼ 0.1. Let the cultures growing at 37°C, shaking at 
220rpm until they reach an OD600 ∼ 0.6. Incubate the cultures on ice for 10 min. Add 
750uM of isopropyl β-D-1-thiogalactopyranoside (IPTG) to induce the over-expression of 
the protein of interest. Protract the over-expression for 16 hours at 20°C. 
2) PKB PH+Kinase (ΔHM motif) constructs, PKB FL constructs, PKB Kinase and 
PKB Kinase+HM: dilute the cells grown overnights in 500 ml of LB media in order to 
have a starting optical density (OD600) ∼ 0.1. Let the cultures growing at 37°C, shaking at 
220rpm until they reach an OD600 ∼ 0.6. Induce the over-expression with 500uM of IPTG. 
Protract the over-expression for 16 hours at 20°C, decreasing the shaking speed to 205 
rpm. In the case of the Danio rerio PKB FL construct the temperature was decreased to 
16°C. 
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3) PKB Kinase+HM S474D: dilute the cells grown overnights in 500 ml of LB 
media in order to have a starting optical density (OD600) ∼ 0.1. Let the cultures growing at 
37°C, shaking at 220rpm until they reach an OD600 ∼ 0.6. Induce the over-expression with 
500uM of IPTG. Protract the over-expression for 1 hour at 37°C, 180 rpm and then 16 
hours at 18°C, 205 rpm. 
4) PDK1 Kinase: dilute the cells grown overnights in 1L of LB media in order to 
have a starting optical density (OD600) ∼ 0.1. Let the cultures growing at 37°C, shaking at 
220rpm until they reach an OD600 ∼ 0.6. Incubate the cultures on ice for 10 min. Induce the 
over-expression with 500uM of IPTG. Protract the over-expression for 16 hours at 18°C.  
5) FAK 31-405 wt: dilute the cells grown overnights in 1L of LB media in order to 
have a starting optical density (OD600) ∼ 0.1. Let the cultures growing at 37°C, shaking at 
220rpm until they reach an OD600 ∼ 0.7-0.8. Incubate the cultures at RT for 30 min. Induce 
the over-expression with 500uM of IPTG. Protract the over-expression for 16 hours at 
20°C.  
Harvest the cell cultures and centrifuge them at 4000xg at 4°C for 40 min, remove 
the supernatant and freeze the pellet at -80°C. 
 
 
 
 
 
 
 
 
 
 
 
 
	  48	  
3.9 Purification of recombinant proteins   
 
Pellets obtained from protein expression (see 3.8) are resuspended in 40 ml of the 
corresponding LYSIS BUFFER (see Tab 3.2) and sonicated on ice for 10 min (6’’on, 
9’’off cycles) at 37% amplitude. All the PKB constructs are gently resuspended at 4°C 
and, then, deep-frozen in liquid nitrogen and thawed three times before the sonication step. 
Cell lysates are centrifuged at 40K rpm at 4°C for 40 min using a rotor 45Ti (Beckman) to 
separate the insoluble fraction (pellet) and the soluble one (supernatant). In the following 
purification step, we process the soluble fraction. All PKB constructs and FAK 31-405 wt 
were initially purified by affinity chromatography, secondly by ion exchange 
chromatography and finally by a size-exclusion step, whereas PDK1 Kinase was purified 
in two-step purification, including affinity and size-exclusion chromatography. Beads, 
buffers and columns used along these purification steps are indicated in Tab. 3.2. 
  
3.9.1 Affinity Chromatography 
 
Based on the TAG fused to the expressed protein, add the indicated resin (2ml/L of 
protein expression) to the soluble fraction and incubate the samples 2hours max at 4°C in 
the case of chelating beads or for 16 hours at 4°C in the case of glutathione Sepharose 
beads (see Tab. 3.2). The beads are then washed as follow: 1) 3x3 column volume (CV= 
ml of beads) of WASH BUFFER 1; 2) 4x2 CV of WASH BUFFER 2; 3) 5x1 CV of 
ELUTION BUFFER (see Tab 3.2). When necessary, the TAG fused to the protein is 
removed by incubation of the eluted protein with TEV protease (1:20 concentration ratio 
protease/protein of interest) at 4°C for 16 hours. The TAG is kept in PKB Kinase, PKB 
Kinase+HM, PKB Kinase+HM S474D and PDK1 Kinase. Eluted protein are dialysed at 
4°C for 16 hours, using Spectra/Por® membrane dialysis MW 6-8000Da, 32 mm 
(SpectraLabs.com) or directly diluted to reach the NaCl concentration of the corresponding 
BUFFER A (Tab 3.2). 
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3.9.2 Ion Exchange Chromatography 
 
According to the pI predicted by ExPASy, the different constructs were further 
purified as follow: 1) by cathion exchange chromatography (PKB PH domain, PKB 
PH+Kinase wt, PKB FL constructs); 2) by anion exchange chromatography (PKB 
PH+Kinase T309A, PKB PH+Kinase T309D, PKB Kinase, PKB Kinase+HM, PKB 
Kinase+HM S474D, FAK 31-405 wt). SOURCE columns (GE Healthcare), indicated in 
Tab. 3.3, are equilibrated in the corresponding BUFFER A and then the proteins injected 
are eluted with different gradients of BUFFER B as indicated in Tab3.2. The eluted 
fractions are loaded on a 12% polyacrylamide gel (see 3.10) and then stained by 
Coomassie solution to discriminate the fractions containing protein bands of the correct 
molecular weight. 
 
3.9.3 Size-exclusion Chromatography 
 
As final step of purification the proteins are injected on a SUPERDEX 16/60 (GE 
Healthcare), previously equilibrated with the corresponding GF BUFFER (see Tab. 3.2). 
After running the eluted fractions on a 12% polyacrylamide gel as described, the fractions 
containing the protein of interest are pooled and concentrated in Amicon Ultra-4 
Centrifugal Filter Units (Millipore) with a porous membrane with a molecular weight cut-
off of 10000 Da, to a maximal concentration variable from protein to protein, as indicated 
in Tab. 3.2 
	  50	  
 
	  51	  
 
Tab. 3.2- Resine beads, buffers and column used during the different steps of purification. A) Affinity 
chromatography. “Protease inh” refers to the Complete EDTA-free protease inhibitors (Roche). Nickel 
Sepharose Fast flow (GE Healtcare) and Glutathione Sepharose beads (GE Healthcare) are equilibrated 
according to manufacturer; B) Ion exchange chromatography; B) Size exclusion chromatography. 
 
3.10 Electrophoresis on polyacrylamide gels 
   
3.10.1 Denaturant conditions (SDS-PAGE) 
 
The electrophoresis in denaturant conditions (SDS-PAGE) is performed using 
discontinuos polyacrylamide gels (Laemmli UK, 1970) made of a mix of acrylamide: 
bisacrylamide (37.5:1). SDS- PAGE gels are made of a stacking gel, constantly at 5% 
acrylamide in Stacking buffer (see 3.1), and a resolving gel whose acrylamide percentage 
can vary according to the molecular mass protein separation needed. Therefore, 15% 
acrylamide resolving gels are prepared for PKB PH domain and 12% for the rest of the 
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protein constructs, using Resolving buffer (see 3.1). Protein samples are diluted in 5X 
Laemmli loading buffer (see 3.1), and incubated at 95°C for 5min. The electrophoresis is 
run in MGV-402 Dual vertical mini-gel electrophoresis system (CBS Scientific) at 190V in 
running buffer. We used the Precision Plus ProteinTM Prestained Standard Dual color 
(Biorad) as a protein marker. Gels are finally stained in Coomassie solution and destained 
in Destaining solution (see 3.1). 
 
3.10.2 Isoelectric focusing (IEF) 
 
The Isoelectric focusing electrophoresis (IEF) is performed using “pH 3–10 Ready 
Gel® IEF Gel” (Biorad) as indicated by the manufacturer. 4ug of PKB constructs were 
loaded and the Anode and Cathode buffers provided by the manufacturer were used. Gels 
are run at 4°C as follow: 1) 100V for 1 hour; 2) 200V for 1 hour; 3) 500V for 30 min. The 
gel is uncast and fixed in Trichloroacetic acid (TCA) for 15 min and then extensively 
rinsed in water. Gels are finally stained in Coomassie solution and destained in Destaining 
solution (see 3.1). 
 
3.11 Western Blotting (Immunoblotting) 
 
After separation on SDS-polyacryamide gel (see 3.10.1), proteins were transferred at 
20V for 40 min onto nitrocellulose membranes (AmershamTM Hybond ECL) using a 
Trans-blot SD semi-dry transfer cell (Biorad). Nitrocellulose membranes are then blocked 
in TBS-Tween buffer, containing 5% Bovine Serum Albumine (BSA) at RT for 1 hour. 
Blotted membranes are washed 3x10 min with TBST and incubated at RT with the specific 
primary antibody as indicated in Tab 3.3. Perform 3x10 min washes with TBST and then 
incubate the membranes with the specific HRP-conjugated secondary antibody, as 
indicated in Tab 3.3. Perform again 3x10 min washes with TBST and detected using a 
standard chemilunimescence Western Blot protocol (ECL system, Amersham). 
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Tab. 3.3- Antibodies list. “Species” refers to the source of purification of the antibody. Dilution used in 
immunoblotting (WB) and ELISA assays are shown. 
 
3.12 Mass spectrometry 
 
All reagents used for protein mass determination were of LC-MS quality when 
available. Samples were desalting immediately before analysis to prevent protein 
precipitation. Proteins were diluted 1:10 in LC-MS grade water containing 0.1% (v/v) 
trifuoroacetic acid. Samples were applied to a home-made Poros 20 R2 tip microcolumn 
(Applied Biosystems Foster City, CA)  previously equilibrated with the same buffer.  
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Columns were washed three times with 200 uL of water containing 0.1% Acetic acid and 
eluted with 250 uL elution buffer consisting in a mixture of 65/35 Acetonitrile/Water (v/v) 
containing 2.5% Acetic acid. Desalted proteins were adjusted to a concentration of 1 ug 
mL-1 in elution buffer and analyzed by electrospray in a maXis QQ-TOF (Buker Daltonik, 
Bremen, Germany) Samples were infused  at a flow rate of 3 uL min-1 and a  capillary 
voltage of 4500V. Mass spectra were recorded from 500 to 2000 Da for 120 to 240 
seconds. Spectra were analyzed using the DataAnalysis 4.0 program (Bruker Daltonic) To 
calculate the mass of the proteins the signals were deconvoluted by using the MaxEnt 
program, a charge deconvolution method based on the Maximum Entropy algorithm. 	  
3.13 ThermoFluor assays 
 
To assess the thermal stability of designed proteins we used the ThermoFluor assay, 
a quick, dye-based assay that allows the determination of melting temperatures (Tm) as an 
alternative to Circular Dichroism. 40ul reactions are prepared as follow: 1 uM of protein of 
interest, 200X SYPRO® Orange dye (Invitrogen). We used Micro-AmpTM Optical 96-well 
reaction plate (Applied Biosystems). The plate was heated from 20°C to 95°C and the 
temperature was increase with a rate of 1°C /cycle. As the temperature increases, the 
protein unfolds, and the increase in fluorescence is monitored using a 7300 Real Time PCR 
system (Applied Biosystems). Melting temperatures are determined as described in 
Lavinder et al, 2009.  
 
 
3.14 In vitro PDK1-dependent PKB T309 phosphorylation assays 
 
Fully-phosphorylation of PKB constructs at T309 is performed as follow: 20uM of 
PKB constructs are incubated at RT for 4 hours with 1uM of PDK1 Kinase, 2mM ATP and 
4mM MgCl2 in PDK1 Kinase GF BUFFER. Add 20mM EDTA to stop the reactions. 
Isoelectric focusing gel (IEF) and immunoblotting with anti-phosphoT309 (Cell 
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Signalling) are run to check the complete phosphorylation of PKB constructs (as described 
in 3.10.2 and in 3.11). Time courses of PKB phosphorylation are performed in 20ul 
reaction at RT using 400nM PKB constructs, 100nM PDK1 Kinase, 1mM ATP and 2mM 
MgCl2. Reactions were stopped at different time points (0’-2’-10’-30’) by addition of 3X 
Laemmli loading buffer, 20% EDTA for immunoblotting analysis or in ELISA binding 
solution, 20% EDTA for ELISA assays. Phosphorylation rate is monitored by 
immunoblotting (see 3.11) and by indirect ELISA assays (see 3.17). When 
phosphorylation timecourses are done in presence of soluble lipids, a final concentration of 
10uM phosphatidylinositol (3,4,5)-triphosphate (PIP3) (Echelon) is added. 
 
3.15 In vitro λ  phosphatase treatement  
 
0.2 ug/ul PKB constructs in 30ul reaction are incubated at 30°C for 40 min with 1ul 
of λ protein phosphatase (New England BioLabs), 1X NEBuffer for PNP (New England 
BioLabs) and 1mM MnCl2. Isoelectric focusing gel (IEF) of pre-treated and after-treated 
samples are run to check the complete dephosphorylation of the protein of interest. 
 
 
3.16 Kinase activity assays 
 
PKB constructs activity has been measured by a coupled kinase assay, where ATP 
hydrolysis is coupled to the transformation of pyruvate in lactate in presence of pyruvate 
kinase (PK) and lactose dehidrogenase (LDH). In this assay we monitor the absorbance of 
NADH during its oxidation to NAD+ by UV absorption at 340nm. NADH absorbance 
decreases when ATP is hydrolysed to ADP. Kinase assay reaction were performed in 
100ul reaction mixture, containing 1 µM of unphosphorylated PKB construct or 0.1 uM of 
phosphorylated PKB constructs, 20 mM HEPES pH 7.0, 100 mM NaCl, 2 mM TCEP, 10 
mM MgCl2, 100 mM phosphoenolpyruvate, 0.28 mM NADH, 0.08 units/µl pyruvate 
kinase, 0.1 units/µl lactate dehydrogenase (SIGMA), and 50 µM of peptide substrate 
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ARKRERTYSFGHHA (Bio-Synthesis Inc). Reactions were initiated by addition of 
0.5mM ATP. Absorbance at 340 nm was monitored during 20min using a Jasko V550 
spectrometer (Advanced Technology & Industrial Co). When kinase assays were done in 
presence of soluble lipids, a final concentration of 10uM phosphatidylinositol (3,4,5)-
triphosphate (PIP3) (Echelon) or 10uM of phosphatidylcoline (PC) was used. Lipids and 
PKB constructs were incubated 20 min at RT before the addition of the mix. 
 
3.17 Enzyme linked immunosorbent assay (ELISA) 
 
We quantified the phosphorylation by PDK1 of different PKB constructs by ELISA. 
Samples from PDK1 phosphorylation reactions were diluted 15 times to a final volume of 
300uL of ELISA binding buffer to a concentration of 27nM. 50uL of this final dilution is 
added to Nunc Maxisorp 96-well Clear Plates wells in duplicate or triplicate. Each plate 
contains as a standard 2-fold serial diluted PKB FL, previously fully phosphorylated by 
PDK1, in the concentration range 0-27nM. Allow the incubation of the diluted reaction and 
standards at RT for 2 hours on a plate shaker at 300rpm. Wash with 2x200ul/well of PBS 
and shake dry. To block wells incubate with 200ul/well of TBS- 5% BSA at RT for 1 
hours on a shaker. Wash with 2x200uL/well of PBS-T and shake dry. Incubate at RT for 1 
hour on a shaker with 100ul/well of anti phospho-AKT (Thr308) (Cell Signalling), diluted 
as indicated in Tab 3.3. Wash with 2x200uL/well of PBST and shake dry. Incubate at RT 
for 1 hour on a shaker with 100ul/well of HRP-conjugated anti-Rabbit antibody (Dako) 
diluted as indicated in Tab 3.3. Wash 4x200uL/well of PBST, allowing last wash to run on 
plate shaker while set-up for detection is done. Add 100uL/well of TMB Solution 
(Calbiochem) and allow shake on plate shaker. Once colour development of the standard 
wells is in an appropriate range (20sec-1min), add 100uL/well of ELISA stop solution. 
Read the absorbance of all wells at 450 nm wavelength, using Varian Carey 50 Bio 
UV/Visible spectrophotometer (McKinley Scientific). Optical density (OD) values are 
converted to concentration of phospho-protein using a non-linear fit of phosphorylation 
standards, using the program Prism (GraphPad Software Inc.). Results are displayed as 
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Arbitrary Units (AU), or fold-change relative to the values of the full-length WT construct 
at 30 minutes. 
 
3.18 Fluorescence polarization 
 
To perform protein-lipid interaction studies we used Fluorescence Polarization (FP). 
This technique exploits the fact that when a fluorescently labeled molecule is excited by 
polarized light, it emits light with a degree of polarization that is inversely proportional to 
the rate of molecular rotation. Increasing concentration of PKB constructs (18.5nM, 39nM, 
78.1nM, 312.5nM, 625nM, 1.25uM) were added to 12.5nM of fluorescence 
phosphoinositide in buffer 20mM Hepes pH7.5, 150mM NaCl, 1mM TCEP and incubated 
20 min at RT. C6-PIP3 (Echelon) is labelled by a BODIPY®-TMR probe (544/570nm), 
whereas C6-phosphatydilinositol (4,5)-bisphosphate (C6-PIP2) (Echelon) is labelled by a 
BODIPY®-FL probe (505/513nm). Anisotropy measurements were taken at RT using an 
EnVision® Multilabel Reader (Perkin Elmer) in presence of C6-PIP3 and using a VICTOR2 
Multilabel Counter (Perkin Elmer) in presence of C6-PIP2. Binding curves and dissociation 
constants were determined using the program Prism (GraphPad Software Inc.). 
 
3.19 Cell lysate substrate specificity assay 
 
Hela cells were cultured in serum free media, Dulbecco’s Modified Eagle Media 
(DMEM) (Solmeglas) for 16 hours. Cell were centrifuged at 1500 rpm for 5 min and then 
cell pellets were washed twice with ice cold 1X PBS. Cell pellets were resuspended in 
300µl of kinase lysis buffer (20 mM Hepes pH 7.4, 5 mM MgCl2 and 0.5 mM EGTA, 100 
µM ATP, 1 mM DTT) and in 300ul of kinase lysis buffer in presence of 0.1mM 
orthovanadate, inhibitor of protein tyrosine phosphatase. 1/3 volume of glass beads 
(particle size 425-600µm) (Sigma) was added to the resuspended pellets. Samples were 
vortexed at maximum speed for 30 sec and then transfer on ice. This step was performed 
twice to completely break the cells. Cells were then centrifuged for 10 min at 4°C at 
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13000rpm and then the supernatant was collected. Cell lysate were aliquoted to have 
500ug/tube in a final volume of ∼30ul. Then, 1µg of unphosphorylated or phosphorylated 
PKB constructs was incubated with cell lysate at 30°C for different time points (0, 5, 20 
min) and stopped by addition of Laemli 5X Sample buffer. Following SDS-PAGE gels 
were processed for immunoblotting with the indicated proteins to detect the 
phosphorylation level of PKB substrates using specific antibodies (see Tab 3.3). 
 
3.20 Screening of fluorinated compounds 
 
3.20.1 Primary 19F-NMR screening 
 
The CNIO library of fluorinated compounds, a small fragment-oriented library of 
371 chemically diverse fluorinated compounds, was used for the primary screening. The 
collection of fluorinated molecules for fragment-based screening using 19F-NMR was 
assembled using three different sources (Garavís, M. et al., 2014): 1) 113 compounds were 
selected using the LEF (Local Environment of Fluorine) approach (Vulpetti, A. et al., 
2009) and purchased individually from different vendors (Maybridge, Sigma-Aldrich, 
ChemDiv, Enamine, Asinex); 2) 210 compounds available in house at CNIO and 3) 53 
selected compounds from commercially available collections. 
The fluorinated fragments have been grouped in two categories, those having a 
trifluoromethly group (CF3) and those having a fluorine atom only (CF) because of the 
different resonances of the fluorine atom, from -9.9 ppm to 26.6 ppm and from -64.0 ppm 
to -19.1 ppm for CF3 and CF containing fragments, respectively. Compounds were 
grouped therefore in 34 cocktails of CF3 fragments (244 CF3 fragments) and in 17 
cocktails of CF compounds (127 CF fragments). A cocktail stock contains typically 
between 8 and 10 fragments at 10 mM each in deuterated dimethylsulfoxide (d6-dmso) and 
each fluorine signal is unambiguously assigned to an individual fragment. The primary 
screening consists in the acquisition of two 19F-NMR spectra of the cocktail samples at 20 
µM each (for CF3 fragments) or 50 µM (for CF fragments) in PBS-1x, 10% D2O, a regular 
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1D, and a 1D with a CMPG T2 relaxation filter of 200/400ms (for CF/CF3) that results in a 
further decrease of signal intensity due to relaxation during this time. Consecutive protein 
additions at fragment:protein ratios of 100:1 and 50:1 result in a increase of line width and 
a decrease of intensity for the fluorine signals of binders whereas fluorine signals from 
nonbinding compounds remain unmodified. The primary screening of the fluorinated 
fragment library can be performed in less than two days with samples exchanged 
automatically by an automated sample exchanger with capacity of 120 samples. 
 
3.20.2 Validation of FERM primary hits 
 
Validation of the primary hits was performed by using three independent techniques: 
1) 19F and 1H-NMR and 2) Surface Plasmon Resonance (see 3.21). Samples of the 
individual hits were prepared at 100 µM in PBS-1x, 10% D2O for NMR experiments. As in 
the primary screening, two 1D 19F-NMR experiments (without and with relaxation T2 
filter) were recorded for the individual hits and they were used as reference for the 
successive additions of protein (typically five consecutive protein additions from a 100:1 
hit:protein ratio up to a final 20:1 hit:protein ratio were done). The interactions were 
confirmed by independent 1H-RMN experiments, both Saturation-Transfer Difference 
(STD) (Mayer, M., Meyer, B., 1990) and WaterLOGSY (Dalvit, C. et al., 2001) 
experiments were measured at the highest protein:hit ratio (1:20). STD NMR measures the 
decay of the intensity of the signals of a protein bound compound after selective saturation 
of protein protons. WaterLOGSY measures the selective intermolecular magnetization 
transfer from water via protein (protein-bound water, exchanging protons) to temporarily 
binding ligands. Protons of binding ligands have the same sign as protein signals whereas 
non-binding compounds give signals of opposite sign. 
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3.21 Surface Plasmon Resonance 
 
3.21.1 Fragment screening 
 
Surface Plasmon Resonance (SPR) monitors molecular interactions between 
molecules in real time by measuring changes in the concentration of the molecules at the 
sensor surface as molecules bind to or dissociate from the surface. One binding partner is 
therefore immobilized over the sensor surface and the other passed over the surface in a 
continuous flow of sample buffer. All biosensor data was recorded on a Biacore X100. 
FERM was immobilized on a CM5 sensor chip using standard amine-coupling chemistry 
at 20 °C. PBS-P+ (20 mM phosphate, 2.7 mM KCl, 137 mM NaCl, 0.05% Surfactant P20, 
pH 7.4) was using as running buffer. First, the carboxyl groups from the dextran matrix 
were activated by a 1:1 mixture of 0.4 M 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
hydrochloride (EDC)/0.1 M N-hydroxy succinimide (NHS) and then coupled to the amine 
groups of FERM. FERM was diluted at 50 µg/ml in 10 mM sodium acetate (pH 5.52) for 
the coupling reaction. Then, 1 M ethanolamine-HCl (pH 8.5) was flown over the surface to 
block the unreactive activated carboxyl groups. FERM was immobilized at density of ~ 
8000 RUs using 4 µg of protein in total. 
Once, the protein is immobilized over the chip, a procedure called solvent correction 
should be done to adjust measured SPR responses for the effects of varying concentrations 
of dmso. A series of blank buffer injections with different percentages of dmso (in a range 
that includes the percentage of dmso used to solubilize the fragments) are passed over the 
surface and a solvent calibration curve is obtained. Finally, fragments at 50 µM in PBS-P+ 
buffer supplemented with 2% dmso were flown over the surface. Biosensor data for the 
fragments were collected at 20 °C and a flow rate of 10 µl/min. Each fragment was injected 
for 60 s association and 300 s dissociation. Positive and negative controls (hit10 or hit17 at 
50 µM and running buffer) were injected throughout each experiment to assess stability 
and reproducibility of the assay. All SPR data were solvent corrected and double-
referenced for blank injections and reference surface. SPR responses at equilibrium 
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normalized by the molecular weight of the fragments were used as a metrics for the 
interaction. 
 
3.21.2 Affinity Measurements 
 
The affinity constant for the interaction between Hit17 and FERM was measured by 
SPR. Increasing concentrations of Hit17 (from 31.25 µM up to 2 mM) were passed over 
FERM immobilized on the surface. The average steady-state responses (over 5s, 10 s 
before the end of the hit injection) were plotted against the ligand concentration and the 
data fitted to a 1:1 steady-state affinity model. 
 
3.22 Crystallization 
 
Crystallization screening of PKB constructs (see Results) were performed with a 
Cartesian MicroSys robot (Genomic Solutions) using the sitting- drop method in 96 wells 
MRC plates (Molecular Dimensions) with nanodrops of protein and reservoir solution. The 
PKB constructs and the conditions tested are explained in Results.  
Crystallization of FAK 31-405 wt was performed using the hanging-drop method in 
24-wells VDXm greased- plates (Hampton Research). Reservoir solution contains 100mM 
Tris HCl pH 8.5, 10mM TCEP, increasing concentration of PEG-4000 (from 16.5% to 
19% with 0.5% increments) and of MgCl2 (from 250mM 325mM with 25mM increments). 
500ul of reservoir volume was used. 0.75ul of reservoir solution was added to 0.75ul of 
8mg/ml protein on a plastic coverlid (Molecular Dimensions, sealed on top of the reservoir 
solution and incubated at 18°C. Crystals grow in appr 2-3 days. 
 
3.23 Soaking and Fishing of crystals 
 
To soak FAK 31-405 wt crystals with the chosen inhibitor (see Results), single 
crystals were transfered in a drop of a cryo-protecting buffer, corresponding to the buffer 
of the crystal growing condition, supplemented with 15% Ethylene glycol and 10mM of 
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fluorinated compound at 20°C for 5 hours. Then crystals were flash-frozen in liquid 
nitrogen. 
 
3.24 Data collection and integration 
 
Data were collected at beamline XO6SA at the Swiss Light Source (SLS) at the Paul 
Scherrer Institut (PSI- Villigen, CH) to a resolution of 2.6-3.4 Ångström (Å). For each 
crystal 400 images were collected with a oscillation (Δφ) of 0.5° at 1.0 Å. Integration of 
the data was performed with iMOSFLM 7.0.9 (Leslie, A.G.W, 1992- Battye et al, 2011) 
and scaled with SCALA (Evans, 2006), as implemented in CCP4 Suite 6.4.0. 	  
3.25 Structure determination and refinement	  
 
Phases were obtained using the FAK FERM structure (pdb code: 2AEH; Ceccarelli 
et al., 2006), which was solved from isomorphous crystals. Refinement was performed 
using the program Refmac (Murshudov et al., 1997) and manual rebuilding using the 
molecular graphic program Coot (Emsley and Cowtan, 2004). When new density was 
observed, the fluorinated compound used previously in the soaking (see 3.23) was 
manually placed into the density, using Coot and the resulting model was further subjected 
to refinement. For a complete summary of data collection and refinement parameters see 
Tab. 4.4 in Results. 
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4.1 PKB  
 
4.1.1 PKB β  isoform is more soluble in E. coli than the α  and γ  isoforms 
Since the regulatory elements we study are conserved among the PKB isoforms, we 
started working in parallel with the three PKB isoforms (α, β and γ) to investigate which of 
them was the most suitable to obtain soluble protein for our studies. For each of them we 
cloned a construct lacking the C-terminal HM motif, named PH+Kinase, into a pET HisTT 
vector (see 3.2). The original codifying sequences for PKB were provided by Dr. Brian 
Hemmings (FMI-Basel-CH) in a pFastBac vector, used for high-level expression of 
proteins in insect cells using the baculovirus system. In fact, PKB is traditionally expressed 
in insect cells as reported in previous work (Yang et al. 2002a). However, we decided to 
initially test the possibility of expressing PKB constructs in E.coli. Bacterial expression 
has the advantages of fast and cheap production of potentially large amounts of protein, as 
required for X-ray crystallisation experiments. However, multi-domain eukaryotic proteins 
expressed in bacteria often are non-functional and frequently are not folded correctly 
resulting in insoluble protein (Baneyx 1999). We transformed E. coli cells (BL21-DE3) 
with the PH+Kinase constructs of the different PKB isoforms. The γ isoform appears to be 
toxic for bacterial cells, therefore we performed a preliminary small-scale expression test 
of only of PH+Kinase α and β. A large amount of α isoform turned out to be insoluble, 
whereas the overexpressed PKB β appears to be mostly soluble (Fig. 4.1A). Then we 
purified both isoforms by affinity chromatography, using a N-terminal His tag that was 
appended during the cloning step in the pET vector (see Materials and Methods). As 
shown in Fig. 4.1A, the yield of eluted protein after Nickel pull down is higher for PKBβ, 
so we decided to work with this isoform. PKBβ PH+Kinase (residues 1- 435) expression 
was scaled up and purified firstly by affinity chromatography. This construct is easily 
overexpressed in E.coli and most of the protein is soluble, allowing us to have enough 
protein for our studies. On the other hand the level of purity obtained was not sufficient for 
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our goal, therefore the eluted His-tagged PH+Kinase was secondly purified by size 
exclusion chromatography, to obtain a higher level of purity (Fig. 4.1B).  
 
Fig. 4.1 Purification and biophysical characterization of His-tagged PKB PH+Kinase.  A) Comparison 
of small-scale Nickel pull-down of α and β isoform of His-tagged PKB PH+Kinase by SDS-PAGE. BI, 
before induction; AI, after induction; IL, insoluble lysate; SL, soluble lysate; FT, flow-through; BB bead 
before elution, EL elution, BA, beads after elution. The red arrow points to the bands corresponding to the 
molecular weight expected for His-tagged PKB PH+Kinase. B) Size-exclusion elution profile of His-tagged 
PKB β PH+Kinase wt (red trace) compared to the elution of different standards (dashed traces). The 
chromatographic profiles (Superdex200) are monitored by absorption at 280nm. Peak fractions (green line) 
were analysed by polyacrylamide gel electrophoresis (SDS-PAGE), shown in the insert below. C) Intact-
mass spectrum of His-tagged PKBβ PH+Kinase wt. The major peak, highlighted by a red arrow, corresponds 
to the predicted molecular weight for His-tagged PH+Kinase wt. D) Circular dicroism experiments (left) 
suggest folded protein with mixed α/β content. The melting temperature (Tm) was measured by monitoring 
thermal unfolding at 220 nm in the CD spectrum (right). 
In order to check whether the purified protein contains any modification or 
degradation we carried out intact mass spectrometry and observed that the molecular 
weight corresponding to the major peak firs with the predicted molecular weight for His-
tagged PH+Kinase (Fig. 4.1C). Moreover, we performed circular dichroism spectroscopy 
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analysis (CD) to validate the secondary structure properties of the protein sample that, as 
expected, showed a mix composition of alpha helix and β sheet conformation. Thermal 
unfolding experiments confirmed that the purified His-tagged PH+Kinase is stably folded 
with a Tm of 52.3°C (Fig. 4.1D). 
 
4.1.2 Expression and purification of PKB β  constructs from E.coli  
 
In order to study the role of the different PKB domains we designed several 
constructs of the β isoform of PKB. Besides the full-length constructs, we cloned shorter 
versions of PKB in order to cover the different combination of domains as shown in Fig. 
4.2. In addition we wanted to control the phosphorylation state of the two main 
phosphorylation sites of PKB, Thr309 and Ser474. Therefore, we generated mutant PKB 
forms where Thr309 and Ser474 are substituted by alanine (T309A) to prevent the 
phosphorylation or aspartate (T309D and S474D), to mimic phosphorylation. All the 
constructs were cloned in pET His TT, transformed in E.coli (BL21-DE3) and initially 
purified by a two-step purification composed of His tag- affinity and size-exclusion 
chromatography as previously described for PH+Kinase. Subsequently, we decided to 
optimize the purification procedure, because the resulting proteins contained impurities 
and failed to crystallize (see 4.1.5). To this end, we cleaved the 6xHis tag in the protein 
eluted by affinity chromatography and we introduced an ion exchange chromatography 
step before the size-exclusion one. All the constructs purified behaved similarly, even if 
the PH+kinase constructs are generally more soluble compared to full-length and ΔPH 
domain constructs. Also the presence of the phospho-mimetic mutation S474D increases 
the yield both for full-length and ΔPH domain constructs. To minimize degradation, all 
purification steps were performed at 4°C in the shortest time window possible. For ΔPH 
domain constructs it was most difficult to obtain sufficient amounts of soluble protein for 
our studies. In order to improve the solubility of these constructs we added low 
concentrations of Tryton (0.1%) to the lysis buffer. Furthermore, these constructs were 
very prone to degradation especially after removing the His tag, therefore we decided to 
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keep the tag in these constructs, after verifying that it had no affect in our assays. Further, 
after testing various lysis conditions, we increased the pH and Glycerol concentration to 
further help the protein stabilisation. Unfortunately, we were not able to get soluble FL 
T309D protein therefore we use the FL wt construct after phosphorylation of the Thr309 
by PDK1 Kinase. 
 
 
 
Fig. 4.2 hPKBβ  constructs.  Summary of the different hPKBβ constructs cloned. PKBβ comprises three 
functional domains: an N-terminal PH domain (dark blue), a central kinase domain (light blue), and a C-
terminal Hydrophobic Motif (HM) (magenta). T309 and S474 are the two main phosphorylation sites in 
PKB. 
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4.1.3 Optimization of PDK1-dependent T309 phosphorylation  
 
In order to obtain T309-phosphorylated PKBβ constructs, we decided to optimize in 
vitro phosphorylation reactions of PKB T309 by the PDK1 kinase. PDK1 is known to be 
the kinase responsible for T309 phosphorylation. PDK1 is a member of the AGC protein 
kinase family and it comprises an N-terminal kinase domain and a C-terminal plecktrin 
homology domain (PH). For our purpose we decided to clone the kinase domain of PDK1, 
sufficient to correctly phosphorylate PKB, into pET His TT. PDK1 kinase was purified as 
His-tagged protein by affinity chromatography followed by size exclusion 
chromatography. PDK1 kinase overexpression in bacteria appeared to be good and enabled 
a yield and purity suitable to set up phosphorylation reactions of PKB. The two kinases 
were mixed and incubated at RT as described in Material and Methods.  
Phosphorylation trials at 30°C resulted in protein degradation. We checked the level 
of T309 phosphorylation by western blotting using a specific antibody (Fig. 4.3A). Since 
western blotting does not provide quantitative information about the completeness of the 
phosphorylation reaction, we analyzed the unphosphorylated and phosphorylated samples 
by mass spectrometry analysis (Fig 4.3B). Moreover, we monitored the completeness of 
PKB phosphorylation by isolelectric focusing where the proteins separate according to 
their pI (Fig. 4.3C), which is affected by negatively charged phosphates. In further 
experiments we only used IEF analysis to monitor T309 phosphorylation by PDK1. 
Before starting the optimisation of the phosphorylation reaction, all the constructs 
were incubated in presence of λ phosphatase and then run on IEF gels, in order to check 
whether the purified proteins were already in a phosphorylated state. Phosphatase-treated 
samples showed the same pI as the untreated ones, suggesting that the original proteins are 
not in a phosphorylated state. To check whether autophosphorylation of PKB occurs, we 
incubate the constructs in presence of ATP. No shift was observed by IEF, indicating no 
autophosphorylation (Fig. 4.4A).  
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Fig. 4.3 In vitro PDK1-dependent T309 phosphorylation of PKB FL S474D.  A) Schematic of the 
phosphorylation reaction. B) i) Different time points of phosphorylation reaction were analysed by SDS-
PAGE (upper panel) and by western blotting (bottom panel), using a specific phospho antibody for PKB 
T309 (α pThr309). Control PKB and Control PDK1 contain only PKB or PDK1 kinase respectively. ii) IEF 
gel of different time point of phosphorylation reaction. Control PKB refers to the FL S47D in presence of 
2mM ATP and 4mM MgCl2, but in absence of PDK1. C) Comparison of intact-mass spectra of 
unphosphorylated (left) and phosphorylated PKBβ FL S47D after 4 hours reaction. The major peak, 
highlighted by a red arrow, corresponds to the predicted molecular weight for the two forms.  
 
All the constructs were initially phosphorylated at different time points and run on 
IEF in order to define the reaction time required for complete phosphorylation of the 
different samples. As shown in Fig. 4.3C for FL S474D, phosphorylation shifts the 
migration in SDS-PAGE and IEF analysis. Since phosphorylated samples exhibit low 
stability, we always generated freshly phosphorylated samples for their use in our assays. 
Within the different constructs, PH+kinase wt and PKB Kinase showed slow 
phosphorylation and we had to increase the time up to 4 hours to achieve complete 
phosphorylation for all constructs. 
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Interestingly, while we were running phosphorylated samples in SDS-PAGE gel, we 
noticed that the migration of PKB constructs was affected, but only when the HM motif is 
present in the construct (Fig. 4.3A and Fig. 4.4B). Althought in denaturant conditions a 
single phosphorylation should not significantly affect the migration of a protein on SDS-
PAGE, in some specific cases the migration properties has been reported to be affected by 
covalent modification (Kovacs et al, 2003). Indeed, the most common covalent 
modification that induce mobility shift in SDS-PAGE is phosphorylation, when it is 
responsible for strong conformational changes.  
 
 
 
Fig. 4.4 PKBβ constructs phosphorylated in vitro on Thr309 by PDK1 Kinase or treated with lambda 
phosphatase sre analysed by SDS-PAGE gel (Coomassie) and by western blotting (α pThr309). U: untreated; 
λ: lambda phosphatase treated; P: phosphorylated, C: incubation with 2mM ATP and 4mM MgCl2. 
 
4.1.4 Stability of PKB constructs 
 
In order to compare the stability of the purified PKB constructs, we performed 
thermofluor experiments to obtain melting temperatures (summarized in Fig. 4.5A). 
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Fig. 4.5 A) Table summarizing the melting temperatures (Tm) for PKBβ constructs, measured by 
thermofluor analysis. B) Comparison of thermofluor transition curves to show the domain-dependent change 
of the Tm. On the left, overlay of Kinase+HM wt (red) and FL wt (blue) transition curves. On the right, 
comparison of Kinase (red) and PH+Kinase wt (blue) transition curves.  
 
 
The thermofluor results outlined a clear transition for all the constructs. Both the 
addition of the PH domain and the HM motif to the PKB kinase noticeably leads to an 
increase in the melting temperature (Fig. 4.5A, B). Moreover, the highest melting 
temperature is reached in the FL constructs, highlighting a additive effect of PH domain 
and HM in the stabilisation of the protein. These considerations about protein stability 
based on the melting temperature values perfectly reflect our observations during the 
protein purification experiments in terms of solubility and propensity to degrade (see 
4.1.2).  
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4.1.5 Crystallization attempts of PKB constructs 
 
To gain an atomic resolution understanding of the mechanisms that regulate PKB, 
we tried to obtain crystals of inactive and active forms of PKBβ. 
We set up different crystallization trays using the vapour diffusion method. Firstly, 
we explored conditions that had previously been reported to yield PKBα crystals in 
presence of a stabilizing inhibitor (Wu W et al, 2010). Initially, we prepared hanging drops 
of the His-tagged PKBβ PH+Kinase wt and T309A by mixing equal volumes of the 
protein with precipitants, consisting of a range of Na-acetate, Na-citrate (from 30mM to 
300mM) and PEG MME 2000 (from 10% to 30%) at 20ºC. Since we did not obtain 
crystals, we decided to cleave the affinity tag and to introduce an additional ion exchange 
chromatography step (see 4.1) to obtain higher purity of the proteins. Meanwhile, we 
performed thermofluor experiments in order to identify the most suitable buffer 
composition, able to confer a better stability of the protein sample. We used this 
information to change the buffer used in the last step of size exclusion chromatography in 
the purification step, replacing Tris pH 7.5 with Hepes pH 7.0. 
Then, we performed extensive crystallization screening of PH+kinase constructs, 
using a robotic nanodrop dispenser of sitting drops. We tested over 2000 conditions, 
setting up a wide number of commercial sparse matrix screens from Hampton and Qiagen 
Research. We further attempted to vary the parameters tested as summarized in Tab. 4.2. 
As shown, we set up screening at different temperatures (20ºC and 4ºC) and protein 
concentrations. We also prepared drops of the protein incubated in presence of ATP 
analogous (AMP-PNP) and MgCl2, and in complex with a specific PKB inhibitor 
(Inhibitor VIII), to see if this could help the formation of protein crystals.  
The only promising result obtained was the formation micro crystals for PH+Kinase 
T309A in a condition of the Index screen (0.1 M Hepes pH 7.0, 10% PEG MME 5000, 5% 
Tacsimate, 0.01 M TCEP). We tried to optimized this hit both extending the range of the 
precipitants concentration and applying Additive screen (Hampton) to the condition of the 
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good hit. Unfortunately, we did not improve either the size or the shape of the micro 
crystals (Fig. 4.6).  
 
 
Fig. 4.6 Micro crystals of PH+Kinase T309A. On the left, we show the micro crystals of PH+Kinase 
T309A (+) in comparison with a control drop where we replace the proteín with gel filtration buffer (-). On 
the right, we show the same condition in presence of additive.	   
 
We also set up crystallization trails of the PH+Kinase T309D, FL T309A and FL 
S474D without any success. Chemical conditions and parameters tested are summarized in 
Tab. 4.2. We also decided to explore if changing the protein organism could improve the 
crystallization attempt. We cloned express and purify PKB FL wt of Bos taurus, Danio 
rerio and Xenopus tropicalis, the only cDNAs available for PKB in addition to the Homo 
sapiens. We only managed to produce suitable amount of soluble protein for the zebrafish 
(D. Rerio). However, crystallization trays were set up without leading to crystal hits. 
At this point we decide to focus our effort more on functional studies to deepen our 
knowledge on our target behaviour and take advantage from our understanding to improve 
our crystallization efforts in a more rational way. 
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Tab. 4.2 Summary of crystallisation screening and parameters tested for the indicated PKB constructs. 
h: Homo sapiens; dr: Danio rerio (zebrafish). 
 
 
4.1.6 Efficiency of PDK1- dependent PKB phosphorylation in presence and in 
absence of PIP3 
 
To determine how the different PKB domains and of PIP3 regulate the efficiently of 
the PDK1-dependent T309 phosphorylation, we performed time course of phosphorylation 
reactions of the different constructs of PKB in presence and in absence of PIP3, as 
explained in Material and Methods. In our immunoblotting experiments (Fig. 4.7A), we 
observed that the PH domain reduces the efficiency of T309 phosphorylation, as we can 
clearly see comparing the FL constructs with their respective ΔPH mutants. This 
observation implies that the PH domain plays an inhibitory role. Furthermore, the 
constructs carrying the phospho- mimetic mutation S474D show a higher level of 
phosphorylation than the wild type, suggesting that S474D mutation accelerates T309 
phosphorylation. On the other hand, removing the HM results in much lower rates of T309 
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phosphorylation. When PIP3 is added during the time course reactions, the phosphorylation 
reaction is accelerated in the FL constructs. To obtain more quantitative results, we 
measured T309 phosphorylation by ELISA assays in triplicates and we quantified the 
phosphorylation rate of each construct in presence and in absence of PIP3 as a fold-change 
of T309 phosphorylation for PKB FL wt after 30 minutes of reaction and in absence of 
lipids (Fig. 4.7B). 
 
 
 
Fig. 4.7 A) Phosphorylation time course of the different PKBβ constructs in absence or in presence of 
PI(3,4,5)P3 was monitored by western blotting, using a specific antibody recognizing PKB phosphorylation 
at Thr309 (α pThr309). The bottom panels are loading controls run in SDS-PAGE and dyed by silver 
staining.  B) Quantification of phosphorylation time course of the different PKBβ constructs by ELISA 
assays. Observed signals are normalized to time 30 minutes of FL wt in absence of PIP3. 
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ELISA assays confirmed the conclusions from western blotting experiments. As 
expected, the negative control FL T309A shows no signals. Interestingly, for constructs 
containing the HM motif, the reduced phosphorylation rate caused by the PH domain is 
recovered in presence of PIP3, indicating the removal of the inhibitory effect of the PH 
domain upon PIP3 binding. The other clear observation is that the HM motif is required for 
efficient T309 phosphorylation by PDK1 and this effect is further increased if the HM 
motif contains the S474D phosphomimetic mutation. 
 
4.1.7 Activity assays of PKB 
 
To measure the catalytic steady state activity of unphosphorylated and 
phosphorylated PKBβ constructs, we used a coupled kinase assay, where the release of 
ADP, driven by the kinase activity, is directly proportional to the consumption of NADH 
(see Material and Methods). In Fig. 4.8A, the activities of unphosphorylated and 
phosphorylated PKB constructs is shown. The first observation is that phosphorylation on 
T309 by PDK1 is required for any significant activity. The activity of freshly 
phosphorylated samples is measured without PDK1 removal. To test whether the presence 
of PDK1 Kinase affects the measurement, we included a control where PDK1 Kinase in a 
concentration equal to the one present in 0.1uM phosphorylated PKB samples is present. 
No effect was observed. As expected, the T309A mutation in PKB prevents a PDK1-
induced activation. On the other hand, the T309D appears to poorly mimic the 
phosphorylated state of T309. A further important observation is that the HM motif is 
essential for PKB activity, given that ΔHM constructs show no activity (Fig. 4.8A). On the 
other hand, the S474D phosphomimetic mutation is not essential, but increases activity. In 
contrast, the PH domain has an inhibitory effect on the activity, and this is more evident in 
the phosphorylated PKB constructs. Possibly, this inhibition is released by the 
phosphomimetic mutation S474D. In fact, the activities of FL S474D and Kinase+HM wt 
are equal, suggesting that the mutation is responsible of the release of the PH domain. 
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However, since the Kinase+HM S474D exhibits higher activity than Kinase+HM wt, the 
S474D mutation appears also to have a PH indipendent activating effect. 
 
 
 
Fig. 4.8 Activity state of PKBβ  constructs. The catalytic activity of PKB constructs was determined by 
coupled kinase assays. Error bars represent standard deviation from three experiments. A) Comparison 
between unphosphorylated PKBβ constructs (at 1uM) and PKBβ constructs phosphorylated on T309 
(pThr309)(at 0.1uM). Blank: reaction mix without PKB; PDK1: measurement of catalytic activity of 5nM 
PDK1, concentration present in phosphorylated PKB samples. B) Activity comparison of the PKBβ 
constructs containing PH domain, in different phosphorylation states and in presence or absence of 10uM 
C8-PI (3,4,5)P3 or C8-PC. C) Activity of PKBβ constructs phosphorylated at T309 (at 0.1uM), at increasing 
concentration of the substrate peptide (0uM, 2uM, 6.25uM, 12.5uM, 25uM, 50uM, 100uM). The data is fitted 
to Michaelis- Menten Kinetics to derive Km and Vmax, shown in the table on the right. 
 
We also tested whether the activities changed after 20 minutes incubation with 10uM 
of soluble PIP3. For these assays we tested only the constructs containing the PH domain, 
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since it is responsible for PIP3 binding (see 4.1.8). As a non-specificlipid control we used 
phopshoatidyl choline (PC). Surprisingly, the addition of soluble PIP3 had no effect on 
PKB activity (Fig. 4.8B). 
Finally we also measured the activity of T309 phosphorylated PKBβ constructs at 
increasing concentration of the substrate peptide and we fitted the data to Michaelis- 
Menten kinetics to derive Km and Kcat (Fig. 4.8 C). As already suggested from Fig. 4.8A, 
the S474D mutation increases and the PH domain decreases Kcat. Surprisingly, the S474D 
mutation increases the Km for the substrate used, suggesting that perhaps S474D could 
play a role in substrate specificity. On the other hand the PH domain has little effect on 
Km. 
 
4.1.8 Interaction studies in presence of lipids 
 
We pursued protein-lipid interaction studies, using Fluorescence Polarization (FP). 
This technique exploits the fact that when a fluorescently labeled molecule is excited by 
polarized light, it emits light with a degree of polarization that is inversely proportional to 
the rate of molecular rotation. In our studies, we use this property to measure how the 
different states of PKBβ interact with PIP3, labeled with a fluorescent BODIPY-TMR 
probe. We compared both unphosphorylated and T309-phosphorylated PKBβ constructs 
with PKB PH domain alone (Fig. 4.9). Surprisingly, the PKB PH domain shows an 
approximately 2-fold lower PIP3 binding affinity compared to the constructs that have also 
the kinase domain. Perhaps, the interaction between the PH domain and the kinase 
stabilizes the PH domain in a conformation, which is more competent for PIP3 binding. On 
the other hand, we found that the phosphorylation state (pT309 or S474D) and the presence 
of the HM do not affect the affinity. As expected, we did not observe a significant PIP3 
binding affinity for ΔPH constructs. 
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Fig. 4.9 PIP3 affinity of hPKBβ  constructs. The binding affinity of PKBβ constructs to PIP3 was 
determined by fluorescence polarization assays, using increasing concentrations of PKBβ constructs (25nM, 
50nM, 100nM, 250nM, 500nM, 1uM). PIP3 (12.5nM) is labelled by a BODIPY-TMR probe 
(Excitation/Emission wavelenghts = 544/570nm). The binding of the isolated PH domain is compared with 
unphosphorylated and T309- phosphorylated hPKBβ constructs: A) PH+Kinase wt, B) FL wt, C) FL S474D, 
D) Kinase, E) Kinase+HM wt, F) Kinase+HM S474D. A one-site binding model was used to fit curves and 
determine Kds.  
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4.1.9 Role of PKB regulatory elements on substrate specificity in cell lysates 
 
PKB is known to have a large number of cellular substrates. An important 
unanswered question is how PKB is regulated to select specific substrates for 
phosphorylation. In order to answer this question, we designed an in vitro assay in 
collaboration with Dr Mohamad-Ali Fawal and Dr Nabil Djouder, head of  the Growth 
Factors, Nutrients and Cancer group (CNIO, Madrid). We prepared soluble cell extracts of 
unstimulated (starved) human HeLa cells. The starvation of the cells is required to 
downregulate the activity of all the growth factor receptor downstream effectors, including 
PKB and its substrates. We then added the different PKB constructs containing or lacking 
the different regulatory elements and monitored PKB-dependent phosphorylation of 
several known substrates, using phospho-specific antibodies. 
In order to explore the main cellular processes that PKB regulates we chose the 
following four substrates: FOXO for survival, GSK3 for metabolism, p27 for proliferation 
and TCS2 for cell growth (Fig. 4.10).  
 
 
Fig. 4.10 PKB substrates chosen for substrate specificity experiments. Blocking arrows indicate that 
PKB-mediated phosphorylation of these proteins leads to their inhibition. By their PKB-mediated regulation, 
each substrate is involved in the activation of specific cellular processes here highlighted.  
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Interestingly, we observed that some of the regulatory elements of PKB have distinct 
effects on different substrates. In line with our activity studies presented above (section 
4.1.9), we find no significant phosphorylation of substrates in absence of T309 
phosphorylation (Fig. 4.11). On the other hand for FL PKB the S474D mutation is required 
to phosphorylate FOXO3a, but is essential for phosphorylation of GSK3. Strikingly, in 
absence of the PH domain, the S474D mutation is no longer required for GSK3 
phosphorylation. Furthermore, TSC2 phosphorylation is only observed in absence of the 
PH domain. On the other hand, p27 required the simultaneous removal of the PH domain 
and the phospho mimetic mutation S474D (Fig. 4.11A). We also performed the same 
experiments with unphosphorylated and phosphorylated PKB FL constructs in presence of 
orthovanadate, a phosphatases inhibitor, to preserve the phosphorylation of the PKB 
substrates by inhibiting endogenous phosphatases present in cell lysate mixture. In these 
conditions, we monitored only the phosphorylation level of FOXO and GSK3 and, 
surprisingly, the substrate specificity phosphorylation is lost. In fact, in presence of pT309 
FL wt and pT309 FL S474D, FOXO is not anymore phosphorylated, whereas GSK3 show 
phosphorylation (Fig.4.11B). 
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Fig. 4.11 hPKBβ  substate specificity in cell lysates. A) PKB- mediated phosphorylation level of FOXO, 
GSK3, p27 and TSC2 are measured in presence of PKB constructs, which differ for the length and for their 
phosphorylation state (+/- PDK1). B) Phosphorylation level of FOXO, GSK3 and TCS2 in presence of 
orthovanadate. In all the experiments the level of phosphorylation is detected by western blotting using 
specific anti-phospho antibodies (α-p). Specificy antibodies (α) for each substrate and PKB are used to 
control the relative loaded amount. α-Vinculin= loading control of cell extracts. 
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4.2 FAK  
 
4.2.1 Screening of a fluorinated compound library by NMR 
 
In collaboration with Ramón Campos and Blanca López of the Spectroscopy and 
NMR unit at the CNIO, we performed 19F-NMR based screening to detect binding of low 
molecular weight compounds (referred to as fragments: Mw < 300 Da) to FAK 31-405 wt, 
corresponding to the FERM domain of Focal Adhesion Kinase. The Spectroscopy and 
NMR Unit has assembled a collection of 371 fluorinated fragments with good solubility in 
aqueous buffer. The fragment-library is screened in pools eight compounds with well-
separated 19-F signals.  
 
 
Tab 4.3 Summary of the compounds tested by SPR to measure the binding to FERM domain. Red 
numbering refears to hits from 19F-NMR screening. Blue numbering refears to compounds identified by 
computer modelling screening and remarked in literature. 
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Using 1D 19F NMR spectroscopy we were able to monitor the binding of the 
compounds present in each cocktail to the FERM domain by consecutive additions of 
protein (at fragment:protein ratios of 100:1, 50:1 respectively) to each of the cocktails and 
following-up the decrease of intensity of the fluorine signal for the potential binders. 17 
hits for the FERM domain (5.1%) were identified in the fluorine primary screening. 
Thereafter, the individual positive hits were prepared at 100 µM each in PBS-1x, 
10% D2O and two independent NMR experiments were run for hit confirmation: a) 19F-
NMR spectrum (1D and 1D with a CMPG T2 relaxation filter of 200/400ms (for CF/CF3) 
that allows a further decrease of signal intensity due to relaxation during this time) at 
successive additions of protein (typically five consecutive protein additions from a 100:1 
hit:protein ratio up to a final 20:1 hit:protein ratio were done) (Fig.4.11A) and b) 1H 
detected NMR spectrum such as STD and WaterLOGSY at the highest protein:fragment 
ratio (1:20) (Fig.4.11B). 
 
 
Fig.4.12 A) 19F-NMR signal of Hit17 (blue) recorded without (left) and with (right) a 200 ms T2 filter. 
Consecutive additions of FERM (with  a protein:fragment ratio of 1:80 up to 1:20) result in a decrease of the 
intensity of the fragment fluorine signal. The decrease of the intensity is more clearly observed with the T2 
filter. B) 1H-NMR spectrum of Hit17 and FERM at a 20:1 fragment:protein ratio. STD NMR (upper panel) 
and WaterLOGSY (lower panel). STD NMR measures the decay of the intensity of the signals of a protein 
bound compound after selective saturation of protein protons. WaterLOGSY measures the selective 
intermolecular magnetization transfer from water via protein (protein-bound water, exchanging protons) to 
temporarily binding ligands. Protons of binding ligands are of the same sign as protein signals whereas non-
binding compounds give signals of opposite sign. 
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4.2.2 Validation of hits by Surface Plamon Resonance 
 
Surface plasmon resonance (SPR) has been used to monitor the binding of the hits 
summarized in Tab 4.3 to the FERM domain. In addition to the hits confirmed by titration 
NMR experiments, we included two compounds reported to bind the FERM domain: 
1,2,4,5-Benzenetetraamine Tetrahydrochloride (TAH) (Golubovska V. M et al, 2008) and 
5’-O-Tritylthymidine 160 (TP-160) (Golubovskaya V. et al, 2013). Both compounds were 
identified by virtual screening. They are predicted to target the autophosphorylation site 
Y397 (TAH) or the N- terminal FERM domain. FERM was immobilized onto a CM5 
sensor chip using standard amine coupling chemistry, as described in Materials and 
Methods. Individual fragments were tested at 50 µM. The SPR data was solvent corrected 
and the steady-state responses normalized by the molecular weight of the fragments (Fig. 
4.13A). Only four hits showed a response higher than 4RU/MW, corresponding to Hit17, 
Hit18, TAH and TP160 (Fig. 4.13A). Hit 17 showed the highest SPR response; therefore 
we determine the dissociation constant by SPR by passing increasing concentrations of hit 
17 (from 31.25µM up to 2mM) over the immobilized FERM. The fit of the average steady-
state responses (over 5s, 10 s before the end of the hit injection) to a 1:1 steady-state 
affinity model results in Kd of 66.7 µM (Fig.  4.13B). 
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Fig. 4.13 A) SPR responses for the hits analyzed. The SPR signal was normalized to the molecular mass of 
each compound. Red bars correspond to the hits chosen for soaking of FERM crystals. B) Sensorgrams for 
the hit17:FERM interaction (left panel). Steady-state responses versus the hit17 concentration (right panel) 
and fitting to the 1:1 steady-state affinity model (continuous curve), indicating a Kd of 66.76 µM. 
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4.2.3 Crystallization of the FERM domain and soaking with fragments 
identified by NMR 
 
We crystallised the FAK FERM domain as explained in Materials and Methods. 
Crystals grew after two days. We optimised the PEG4000 and MgCl2 concentration and 
found optimal crystallization at  19% PEG4000 and 325mM MgCl2 (Fig. 4.14).  
 
 
Fig. 4.14 FAK 31-405 wt crystals. Bigger size crystals were obtained at higher concentration of precipitant 
and salt (green arrow) after 2-3 days after drops setting. 
 
For soaking experiments of FERM crystals we selected fragments hits that showed a 
response higher than 4RU/MW in the SPR measurements. For soaking, single crystals 
were transferred to a drop contianing a cryo-protecting buffer in addition to the 
crystallisation components (see Materials and Methods) and 10mM of fluorinated 
compound, and incubated at 20°C for 5 hours. Soaked crystals were flash-frozen in liquid 
nitrogen. TP160 displayed low solubility in the crystal buffer condition, and the 
precipitation observed affected the freezing step. Therefore, for this compound, we had to 
wash the soaked crystal in a drop of a cryo-protecting buffer containing only 1mM 
compound, which was the highest concentration where precipitation was not observed.  
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4.2.4 Identification of electron density for positive hits 
 
Diffraction data was collected at beamline XO6SA (SLS) as described in Material 
and Methods. Data was processed using iMOSFLM 7.0.9 (Battye et al, 2011) and scaled 
using SCALA (Evans, 2006). Crystals belong to the P21 spacegroup with approximate cell 
dimensions illustrated in Tab. 4.4. Structure refinement was performed with iterative 
cycles of computational refinement using Refmac5 (Murshudov et al, 1997) and manual 
rebuilding using Coot (Emsley and Cowtan, 2004). For details on data processing and 
refinement, see Tab. 4.4. 
The refined structures were inspected for the presence of large peaks in the Fo-Fc 
difference electron density maps as well as unmodelled peaks in the 2Fo-Fc electron 
density maps. Significant electron density peaks were only observed for crystals that were 
soaked with Hit17 and TAH. 
Hit 17- The resolution of the FERM structure in presence of Hit 17 was of 2.6Å 
(Tab. 4.4). We attempted to place the fluorinated compound manually into the density, 
using Coot. As shown in Fig. 4.15, the density for the compound is not very clear and we 
could not conclusively define the orientation of Hit17. Therefore, we consider two 
potential binding modes (Fig. 4.15). The first consists in the Hit 17 binding into the pocket 
through the methoxy ethane group (Pose 1), whereas the second one through the 1-fluoro-
5-bromobenzene ring (Pose 2). Comparing the chemical interactions that we can observe in 
the different binding modes, does not clearly favour one of the poses. In the Pose 1, the 
methoxy ethane group establishes hydrophobic interactions with Leu197, Met183, Val 196 
and Tyr180. In addition, a salt bridge between the acidic group of the compound and the 
nitrogen of the carboxamide from the Asn193 takes place. In the Pose 2, hydrophobic 
interactions with Asn193, Met 183 and Val196 are established by the 1-fluoro-5-
bromobenzene group, which also forms π-π stacking interactions between the phenyl ring 
of the fluorobrominebenzene and Tyr180. Moreover, the carboxylic group of the 
compound interacts with the nitrogen of the backbone of Arg184 (Fig 4.15). 
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Fig. 4.15 FERM: Hit17 complex. In the upper panel, we compare the two potential poses of binding for 
Hit17. The 2Fo-Fc (blue) at 1 sigma and the Fo-Fc at 2.8 sigma (green for positive and red for negative 
density) maps are shown after refinement with the compound in the respective pose. Water molecules are 
labelled with a red cross. In the bottom panel, the location of Hit17 with the respect to the autoinhibited 
FERM+kinase structure (pdb code: 2J0J) is shown. 
 
TAH- The density was observed in two different crystals. The resolution of the 
FERM structure in presence of TAH was 3.1Å and 3.4 Å respectively (Tab. 4.4). TAH 
electron density is located at the F1 lobe of the FERM domain, close to the site that 
interacts with linker residues containing the autophosphorylation site Y397. TAH closely 
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interacts with Cys74 and also contacts linker residue Ile400. FERM crystallizes as a dimer 
and interestingly TAH is present only in the dimer where the linker of the protein is well 
ordered, suggesting that the linker is increasing the binding affinity (Fig 4.16). 
 
 
 
Fig. 4.16 FERM:TAH complex representation. In the upper panel, we compare the TAH interaction in the 
two FERM molecules in the asymmetric unit, where the linker is present (left) or absent (right). The 2Fo-Fc 
(blue) at 1 sigma and the Fo-Fc at 2.8 sigma (green for positive and red for negative density) maps are 
shown. The density corresponding to TAH is present only when the linker is well ordered (upper left panel). 
In the bottom, we show where TAH binds with respect to the autoinhibited FERM+kinase structure of FAK. 
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Tab 4.4 Data collection and refinement statistics for FERM: Hit17 and FERM:TAH. The dataset was 
collected on one single crystal. Highest resolution shell is shown in parentheses.  
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5.1 PKB  
 
5.1.1 Multiple levels of PKB regulation 
 
As a member of the AGC kinase family, PKB possesses functional domains other 
than the kinase core, which are involved in regulating kinase activity and localization. In 
fact, activation of PKB is regulated at different levels and it involves phosphorylation of 
two highly conserved regulatory motifs: the activation loop (also known as T-loop) in the 
catalytic domain and the HM motif. In PKB, the PDK1 dependent- phosphorylation of the 
T309 in the T loop leads to a partial activation, and phosphorylation of S474 in the HM 
motif by mTORC2 is required for maximal activity (Sarbassov et al, 2005).  
The presence of a PH domain with high affinity for PIP3, induces a PKB 
conformational change and enables an easier accessibility of the T309 for PDK1 
phosphorylation (Calleja et al, 2007). On the other hand, S6K and SGK do not possess a 
PH domain, but their regulation is still mediated by PIP3, which triggers a signalling 
cascade, leading to the phosphorylation of the HM motif. Nevertheless, this 
phosphorylation alone is not sufficient for their activation, but it stimulates 
phosphorylation of the activation loop by PDK1 (Biondi et al, 2001). Uniquely among the 
AGC kinases, PDK1 lacks a C-terminal HM motif, although its N- term lobe hydrophobic 
groove possesses a region named PDK1-interacting fragment (PIF) pocket in its catalytic 
domain, which directly interacts with phosphorylated hydrophobic motifs, including those 
of S6K and SGK (Biondi et al, 2000). In the case of atypical PKC and PKN isoforms, the 
presence of an acidic phospho-mimetic Asp or Glu residue in the HM motif instead of a 
phosphorylatable Ser or Thr residue, seems still to interact with the PIF pocket of PDK1, 
promoting phosphorylation and activation and thereby bypassing the need for the 
phosphorylation of the hydrophobic motif (Biondi et al, 2000). 
Moreover, it has been shown that in tissues from mice expressing a mutant form of 
PDK1 that cannot bind PIP3, PKB is still phosphorylated at the activation segment 
(Bayascas et al, 2008). Therefore, other mechanisms might operate to enable PKB and 
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PDK1 to interact at the membrane or there might be other mechanisms that do not require 
membrane association. 
 
5.1.2 Role of the PH domain in PKB activity and regulation 
 
Our data suggests a regulatory role for the PH domain on different levels. On the one 
hand, the PH domain reduces the rate of the PDK1-driven T309 phosphorylation and 
secondly, it has a direct inhibitory effect on PKB catalytic activity. Interestingly, we find 
that binding of PIP3 to the PH domain is able to restore T309 phosphorylation efficiency. 
Therefore, PKB PH domain would have, then, a dual function on PKB activation 
inhibitory, by the interaction with the Kinase domain, and stimulatory after binding with 
PIP3. This feature has been reported also in previous work, where they also found active 
PKB both in cytosol and at the membrane (Andjelkovic M, et al, 1999). 
Based on dynamic model (Calleja V et al, 2007), it was observed a PH-induced 
cavity in the same region of the PKB hydrophobic pocket. The location of this cavity 
appeared to be in the same region as the PKB hydrophobic pocket (binding site for PKB 
HM) described in the crystal structure of the isolated PKB kinase domain (Yang et al, 
2002). Through this PH-induced cavity, the Trp 80 residue, located at its centre, was 
accessible from outside, whereas PKB remained in its inactive conformation. To explore 
the importance of the positioning of the Trp 80 in the PH-induced cavity, Calleja and 
colleagues took advantage of a specific PKB inhibitor, AKT inhibitor VIII. By docking of 
AKT inhibitor VIII in the PH-induced cavity, they saw that the association of the PH 
domain residue Trp 80 to AKT inhibitor VIII would block PKB in the inactive 
conformation, preventing Thr 308 accessibility for phosphorylation. This was confirmed 
by the crystal structure of PH+Kinase in complex with Inhibitor VIII, obtained in 2010 by 
Wu et al, 2010. 
Moreover a dynamic model done using PKB Kinase+HM S474D crystal structure by 
Yang et al. (PDB code: 1O6K) showed that the HM passed right across the PH-induced 
cavity. Actually Phe 470 and Phe 473 were positioned at a binding distance from Trp80. 
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This result showed that the binding of the inhibitor was not dependent on the C- terminal 
part of PKB and indicated further that the HM and AKT inhibitor VIII could potentially be 
competing for a common or close binding site on the kinase domain. These interactions 
suggested a role for the HM motif in the regulation of PKB prior to its traslocation and 
S474 phosphorylation. To conclude, also the HM motif plays a dual role in the regulation 
of PKB activity. On one hand, it helps in maintaining the inactive conformation of PKB by 
locking the conformation and on the other hand would activate allosterically the kinase by 
rearranging the catalytic site (as reviewed in Calleja V et al 2009). 
 
5.1.3 Role of the HM motif in PKB activity and regulation 
 
From comparison between the inactive and the active structures of PKB kinase 
domain (Yang et al, 2002a- Yang et al, 2002b) the authors concluded that the role of 
Ser474 phosphorylation is to promote the engagement of the HM with the hydrophobic 
pocket in the N lobe of the kinase domain, promoting a disorder-to-order transition of the 
α B and αC-helix and that the αC-helix, in turn, by interacting with pThr309 restructures 
and orders the activation segment, generating an active kinase conformation. The view that 
the phosphorylated HM is the critical factor was supported by the observation that the sole 
T309 phosphorylation was insufficient to allow the reorganization of the catalytic site. Our 
data suggests that both the HM and T309 phosphorylation are essential in stabilizing an 
active PKB conformation (Fig. 4.8A). Moreover, previous work confirmed that the 
combination of pT309 and S474D mutation was at least 2 fold more active than the single 
pT309, like in our kinase assays (Huang X et al., 2003). However, we show that the 
unphosphorylated HM in conjunction with pT309 is sufficient for a substantial level of 
activity and that the HM phosphorylation further increases Kcat of PKB. This suggests that 
the unphosphorylated HM is able to interact with the hydrophobic pocket, albeit with 
lower affinity. This is in fact supported by comparison of PKA structure and PKB 
Kinase+HM structure (Fig.5.1). Most importantly, structural analysis shows that two 
conserved phenylalanine residues (F347 and F350 in the case of PKA) in this motif 
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participate in the anchoring to the core of the C-terminal end, interacting interact 
extensively with the hydrophobic pocket in PKB (Etchebehere L et al, 1997). The FXXF 
motif, where X are usually non- hydrophobic amino acids is conserved in PKA, which 
does not require HM phosphorylation for activation (Biondi et al, 2000). 
 
 
 
Fig. 5.1 Comparison between the N lobe structure of A) PKA, B)PKB Kinase+HM and C) PKB 
Kinase+HM S474D. In contrast with PKA structure, the crystal structures of PKB show that the residues 
corresponding to the region of the αB and αC helices (orange) are disordered in absence of Ser 
phosphorylation. This is correlated with weaker affinity of PKB unphosphorylated HM motif for the N lobe. 
In fact, in presence of a phospho-mimetic mutation S474D, the helices are ordered (from Yang et al 2002a). 
The activation loop is coloured in yellow. 
 
5.1.4 PKB phosphorylation on substrate specificity 
 
Our purified PKB proteins are able to phosphorylate cellular targets in soluble HeLa 
cell extracts. Our results fit with our in vitro studies, in that pT309 and the presence of the 
HM (for PH containing PKB) are essential for PKB activity. We find that the 
phosphorylation state of S474 and the PH domain affect the substrate selectivity of PKB. A 
role of S474 phosphorylation in substrate specificity is also supported by our finding that 
the S474D mutation lowers the affinity for the peptide substrate we used for data shown in 
Fig.4.8C. Such an effect could be amplified for an intact protein substrate. The role of 
S474 phosphorylation in substrate specificity has been investigated previously by studying 
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insulin stimulated cells that are unable to phosphorylate S474D, due to the lack of SIN1 in 
TORC2 (Jacinto E. et al, 2006). Jacinto and colleagues find that phosphorylation on S474 
enhances FOXO phosphorylation but has no significant effect on GSK3 or TSC2. They 
conclude that S474 phosphorylation is not essential for GSK3 or TSC2, which mirrors our 
result for PKB lacking the PH domain. Since insulin stimulation triggers PI3K activity and 
generation of PIP3, it is tempting to speculate that our results with ΔPH-PKB mimics a 
state of PKB bound to PIP3 membranes. On the other hand, their finding that pS474 is 
required for efficient FOXO phosphorylation contrasts with our results. It is possible that 
the pS474 requirement for FOXO phosphorylation is further determined by secondary 
events that are not monitored in either of the two studies. In support of this, we find no 
FOXO phosphorylation if we perform our experiments in presence of the phosphatase 
inhibitor orthovanadate (Fig. 4.11B). This indicates the presence of an inhibitory 
phosphorylation event that prevents FOXO phosphorylation. Possibly the SIN1 deficiency 
in the Jacinto et al study, affects, through secondary effects, the phosphorylation state of 
that inhibitory site, however further studies will be required to fully explain these 
conflicting results. Importantly, our results support a view, where S474 phosphorylation 
and PH binding to PIP3 membranes could determine the subset of PKB substrates that are 
phosphorylated, which could allow PKB to differentially trigger different cellular 
responses (see section 4.1.9).  
Our results in Fig 4.11A further indicate that several cellular substrates can be 
phosphorylated by the isolated kinase of PKB (ΔPH, ΔHM). This contrasts our in vitro 
results that indicate no significant activity on a substrate peptide (Fig.4.8A). Possibly, in 
absence of the PH domain other cellular factors could aid the stabilisation of the αC helix, 
such as HM motifs of natively expressed PKB or other AGC kinases in HeLa cells. 
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5.1.5 PKB structure 
 
Short after starting our study, a crystal structure of PKB PH+Kinase α in complex 
with an allosteric Inhibitor VIII was reported (Wu W. et al, 2010). From the analysis of the 
position assumed in this inhibited structure by Trp80, we pursue the idea of being able to 
crystallize the inactive form of PH+Kinase in absence of the inhibitor.  In fact, comparing 
the position assumed by Trp80 in presence of Inhibitor VIII and the one assumed in the PH 
domain structure bound to Ins(1,3,4,5)P4 (IP4) (Thomas C. et al, 2002), it is clearly visible 
that the side chain of the Trp80 changes significantly orientation. This suggests that the 
variable loop 3 (VL3) shifts in different ways to accommodate various ligands. Based on 
this, we wonder whether the Wu W. et al structure represent a native state of the protein 
and we thought that that without any ligand the indole group of Trp80 was able to establish 
stable hydrophobic interactions with the neighbouring residues, stabilizing the interactions 
between PH domain and Kinase domain in the N lobe adjacent to the ATP binding cleft. 
Unfortunately, this hypothesis turns out to be wrong, since despite all the crystallization 
conditions we tried, we did not manage to obtained crystals of PKB. An explanation can be 
that probably the PH without inhibitor is much more flexible on the loop and this does not 
allow to reach a stable state in the crystallization process. Another reason why we did not 
obtained crystals can sit in the homogeneity of the purified protein. In fact, the foundation 
for a successful crystallization experiment is laid at the purification stage. The purity, 
homogeneity and monodispersity of the protein sample are important parameters prior 
crystallization. Proteins should be as pure, homogeneous and free from structural and 
charge heterogeneity as possible, to aim the growth and the production of crystals suitable 
for x-ray structural analysis (Benvenuti M, et al, 2007). During the optimisation of PKB 
constructs purification protocol, we run the fractions of the main ion exchange 
chromatography peak in an IsoElectric Focusing gel (IEF) to check the heterogeneity of 
the samples. In this way, we clearly observed that the pure protein band seen in a SDS-
PAGE gel hide a mixture of different isoelectric forms of the same protein. For most of the 
constructs we identified two main pools. These two species could be separated on ion 
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exchange and finally purified separately by a size-exlcusion step. A better separation of the 
different species can be obtained using isofocusing chromatography, were proteins are 
separated based on their pI. It would be interesting to try more crystallization screening, 
using the proteins with improved purity. 
 
5.1.6 Suggested model of regulation 
 
From previous work, the scenario of PKB activation is not easily disclosed, but 
several data suggest that different conformational states of PKB exist at various stages of 
PKB activation in vitro. Due to the fundamental role of PKB in many biological processes, 
the need for extensive safety levels has been established in order to prevent unwanted 
activation of the kinase. Canonically, under stimulation of PI3K and production of PIP3, 
PKB is recruited to the inner surface of the plasma membrane by binding with the PH 
domain. Here, PKB is efficiently phosphorylated by PDK1 on T309, resulting in kinase 
activation (Bellacosa et al, 1998). On the other hand, the role of S474 phosphorylation has 
always been controversial. Previous work demonstrated not only the important role of 
S474 in fully activating PKB, but also that prior S474 phosphorylation boosted subsequent 
T309 phosphorylation by PDK1 (Dos D. Sarbassov et al 2005- Huang X et al, 2003). Our 
ELISA data (Fig. 4.7B) agree with this conclusion, confirming that S to D mutant is a 
better substrate for T308 phosphorylation. The two phosphorylation steps are tightly 
connected and interdependent, due to conformational changes in PKB induced by 
phosphorylation as already mentioned (Yang et al 2002) 
Moreover, PH domain mutations that reduce significantly the interaction with PIP3, 
did not preclude the full activation, meaning that the access of the activation loop is 
maintained open by other destabilisation of the interface between the PH domain and the 
kinase domain (Thomas CC, et al, 2002). There is, indeed, an emerging view that S474 
precedes the phosphorylation of T309 and it is important for the recognition and activation 
of PKB by PDK1.  
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Based on our data we propose a model where PKB can follow two distinct pathways, 
one under the growth factor induced PI3K pathway, and the other under the 
mTORC2/DNA-PK one (Fig. 5.2). The first pathway follows mainly the canonical 
activation of PKB, where the PH domain binds to PIP3 and PKB colocalizes with PDK1 to 
the plasma membrane and can be phosphorylated on T309 by PDK1. In this activation 
state, PKB leads to the phosphorylation of cellular substrates, for which the single T309 
phosphorylation and the spatial removal of the PH domain is enough. On the same 
pathway, S474 can be also phosphorylated and specifically activate p27. Our lipid binding 
assays did not show a change in affinity once PKB is phosphorylated on both T309 and 
S474, therefore we do not embrace the theory of a release from the membrane under this 
state. In addition, in our model mTORC2/DNA-PK pathway triggers a membrane 
association-independent PKB activation. PDK1 is recruited to PKB after its 
phosphorylation on Ser474 via the PIF-pocket, hydrophobic docking motif on the PDK1 
kinase. In this case, we speculate that phosphorylated S474 binds to the PIF pocket of 
PDK1 forming a complex of high binding affinity. In this state PDK1 can phosphorylate 
T309 in a membrane independent manner. In this state PKB is able to specifically activate 
GSK3. This was showed, at some extent also in other works, in which PKB T309 
phosphorylation and GSK3 phosphorylation were comparable with/without PI3K 
inhibitors treatments (Bozulic et al, 2008). 
In contrast with our model, it had been previously showed that the PIF-binding 
pocket in PDK1 was essential for activation of S6K and SGK, but it did not appear to be a 
rate limiting for PDK1-mediated activation of PKB (Biondi et al, 2001). Moreover, knock 
in mutations that disrupt the PIF-pocket either in ES (embryonic stem) cells (Collins et al, 
2003) or in mouse muscle (Bajascas et al, 2008), were able to abolish the activation of S6K 
and SGK, but did not markedly affected PKB. Consistent with this conclusion, the ablation 
of S474 phosphorylation and, therefore of the ability of PKB to bind PDK1 PIF-pocket, 
had little impact on PDK1-mediated PKB Thr309 phosphorylation. This was true in 
different mouse model knockout of the mTORC2 components Rictor (rapamycin-
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insensitive companion of mTOR) (Shiota et al, 2006) Sin1 (stress-activated protein kinase-
interacting 1) (Jacinto et al, 2006) or mLST8 (mTOR-associated protein, LST8 
homologue) (Guertin et al, 2006). On the other hand, the physical association of PDK1 
with PKB induced by reconstituted IFP (intensely fluorescent protein) was showed to be 
sufficient to produce T309 phosphorylation and activation of PKB independent of PI3K 
activation or membrane localisation. Moreover, that complex formation stabilized by 
reconstituted IFP also promoted PKB S474 phosphorylation (Ding Z et al, 2010). More 
recently, PKB resulted to be resistant to PDK1 inhibitors whereas ablation of mTORC2 
rendered PKB more susceptible to inhibition by PDK1 inhibitors (Najafov A et al, 2012. 
These data suggest that phosphorylation of Ser474 plays indeed a role in regulating Thr309 
phosphorylation, and they highly support our suggested model. On the other hand, in vitro 
studies undertaken in the presence of lipid vesicles containing PIP3 indicated that mutation 
of Ser474 to alanine had no effect on phosphorylation of Thr309 and activation of PKB 
(Biondi et al, 2001). 
In the scenario, we still support the idea of this model where the activity of PKB is 
under the control of two different pathways, because this can allow maintenance of all the 
functions of PKB also when one of the pathway stops to work properly. For instance when 
the PI3K route is defective, the mTORC2/DNA-PK pathway can trigger the membrane 
association-independent PKB activation. In this respect, it was shown that PKB is 
specifically activated by DNA-PK –dependent S474 phosphorylation, after induction of 
double strands breaks (Bozulic et al, 2008). Further in vitro interactions studies between 
PDK1 and PKB in different states need to be done to add more evidences in support of this 
model. 
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 Fig. 5.2 Model for PKB regulation and activation. PKB can undertake two possible activation pathways, 
differencing by which regulatory site, T309 and S474, is phosphorylated first. According to the 
phosphorylation succession followed, PKB can specifically phosphorylate downstream cellular substrates. 
 
 
5.2 FAK 
 
 
5.2.1 Fragment-based drug discovery: a key contribution of structural biology 
 
Fragment-based screening has rapidly become a proven technique to identify novel 
chemical starting points in drug discovery programs as an alternative to more traditional 
approaches based on chemical derived from high throughput screening  (Erlanson D et al, 
2004). The success of the fragment-based approach is buried, first, in the concept that 
chemical space can be more efficiently probed by screening collections of small fragments 
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rather than libraries of larger molecules. Fragments are low molecular weight compounds  
(typically 100-250Da) that can more easily find binding modes than larger druglike 
molecules (Congreve M. et al, 2008). Unalike druglike molecules, fragment hits show low 
binding affinities to their target protein (micromolar to millimolar range), as the Kd 
measurement of Hit17 confirmed (Fig. 4.13). Once a small molecule positive hit with 
affinity at uM levels has been found, more focused libraries can be rapidly improve by the 
introduction of chemical groups, which simultaneously improve affinity, and the 
pharmacokinetic properties of these molecules (Teague S et al, 1999). Furthermore, the 
rapid optimisation of fragment hits using structure-based design has established fragment-
based drug discovery (FBDD) as a valuable strategy in the search for new drug molecules. 
Structural biology has been increasingly employed as a tool in the screening of fragments 
because it allows facing one of the main problems of the fragment-base drug discovery, 
consisting in the necessity of physical properties information of the ligand binding. In fact 
the structural information can be addressed to optimize efficiently the fragments hits 
(Harsthshorn M et al, 2005). Using this approach, four representative hits were selected 
and further optimise based on structure data, leading to the formulation of a novel cyclin 
dependent kinase inhibitor (CDK) (Wyatt P et al, 2008). Subsequently a structure-based 
approach using CDK2 crystallography resulted in the identification of analogous with good 
activity and ligand efficiency also for Aurora A. Optimization by crystallography 
screening lead to the formulation of an inhibitor against Aurora A (Howard S et al, 2009). 
Moreover, after a library screening of 20000 fragments, multiple fragments that bound to 
Heat shock protein 90 (Hsp90) were identified. Promising hits were submitted to co-
crystallisation and soaking experiments and the fragment hits were rapidly optimised using 
a combination of in silico commercial analogue selection and structure-based design 
(Barker J et al, 2009). 
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5.2.2 Pose 1 versus Pose 2, which is the winner?  
 
As shown in Results, the electron density for Hit 17 does not conclusively define the 
orientation of the Hit17 compound. Therefore, we consider two potential binding modes, 
and the chemical interactions that we can observe in the two poses, does also not clearly 
favour one or the other (Fig. 5.3). The best way to discriminate between the two binding 
modes would be to obtain better define electron density for Hit17. Since the affinity of 
Hit17 should be sufficient to obtain high occupancy of the bound compound, it is possible 
that the soaking protocol we applied does not allow efficient diffusion of the compound 
through the solvent channels in the crystal. Hence, co-crystallization could potentially 
result in improved electron density for Hit17. The resolution of 2.6 Å further limits a 
conclusive interpretation of the density: improvements in the crystallization condition to 
yield higher diffracting crystals could greatly facilitate the interpretation. As a potential aid 
to distinguish between the two possible modes we consider the anomalous signal of the 
bromine in Hit17. To approach this, data will be collected at 0.92 Å, instead of 1.0 Å, in 
order to hit the K absorption edge of bromine and be able to improve the calculation of 
phases by single-wavelength anomalous diffraction (SAD). 
In an alternative approach, we plan to test fragments analogous of the hit17, 
available in the ETP library of CNIO, which either contain the ethoxy-benzene and central 
part or the 1-fluoro-5-bromobenzene ring with the central part of Hit17. Surface plasmon 
resonance analysis of these analogues should indicate which part of Hit17 is essential for 
binding. Once the binding pose is identified, the structural information should allow the 
design of modifications that increase the binding affinity. Strategy that could be followed 
includes replacement of displacement of a nearby water molecule interacting by hydrogen 
bonds with the backbone of the Glu 182 and Met183. The synthesis will be performed at 
the Experimental Therapeutic Programme in CNIO (headed by Joaquin Pastor).  
Interestingly we observe that the allosteric pocket, where Hit17 interacts with 
FERM, lays on the contact interface between FERM and Kinase domain when the protein 
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is in the autoinhibited state (bottom panel of the Fig 4.15). This observation indicates that 
Hit17 could have an activating effect on Focal Adhesion Kinase instead of inhibitory. In 
order to turn Hit17 into an inhibitory compound it would have to be expanded to include 
also an anchor for the kinase domain. Such a bivalent compound could be expected to 
stabilize a closed and autoinhibited FAK conformation. 
 
 
 
 
 
Fig. 5.2 Comparison of chemical interactions in the two binding modes of Hit17. A) Pose 1; B) pose 2. In 
the left panel, Ligplot+ analysis are shown, whereas in the right panel cGRILL analysis of the interactions. 	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1. PKBβ constructs expressed and purified in E. coli are well folded and catalytically 
active. The PH and HM regions stabilise PKB. 
2. T309 phosphorylation and the presence of the HM are essential for PKB activity. 
3. The S474D phosphomimetic mutation increases and the PH domain reduces catalytic 
turnover (Kcat) of PKB. 
4. The S474D mutation affects Km of PKB. 
5. The HM motif is essential for efficient PDK1 mediated T309 phosphorylation of PKB 
and the S474D mutation in the HM further enhances it. 
6. The PH domain reduces the rate of the PDK1-driven T309 phosphorylation; PIP3 
binding to the PH domain restores efficient T309 phosphorylation. 
7. T309 phosphorylation in PKB is essential for phosphorylation of all tested cellular 
substrates. The S474 phosphorylation state and the PH domain are involved in 
substrate specificity.  
8. Our data fits a model where PKB can follow two distinct pathways, which potentially 
can result in activation of different substrates. In the first, PKB is initially 
phosphorylated on T309, after PKB binding to PIP3 at the inner surface of cell 
membrane. In the second, PKB is firstly phosphorylated on S474 and therefore the HM 
preferably interacts to PDK1 PIF pocket, promoting T309 phosphorylation 
9. The FERM domain of FAK can be targeted with small molecule fragment compounds. 
10. We structurally characterise two positive fragment hits interacting with the FERM 
domain of FAK in specific pockets.  Compounds with improved binding affinity can be 
designed on the structural information collected in this work.  
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1. Las construcciones de PKBβ, expresadas y purificadas en E. coli, están bien 
plegadas y son activas a nivel catalítico. Las regiones del dominio PH y del motivo 
HM estabilizan PKB. 
2. La fosforilación de la T309 y la presencia del motivo HM son esenciales para la 
actividad de PKB. 
3. La mutación S474D, fosfomimética, aumenta la constante catalítica (Kcat) de PKB, 
mientras el dominio PH la reduce. 
4. La mutación S474D influye sobre la Km de PKB. 
5. El motivo HM es esencial para que la fosforilación de la T309 por PDK1 sea 
eficaz. En presencia de la mutación S474D, la eficacia es aun más significativa.  
6. El dominio PH reduce la velocidad de la fosforilación de la T309 catalizada por 
PDK1; después de la interacción del dominio PH con PIP3, se recupera la eficacia 
de fosforilación de la T309 . 
7. La fosforilación de la T309 en PKB es esencial para la fosforilación de todos los 
sustratos de PKB examinados. El estado de fosforilación de la S474 junto con el 
dominio PH están involucrados en determinar la fosforilación de estos sustratos de 
manera específica.  
8. Nuestros resultados sugieren un modelo donde PKB puede seguir dos rutas 
distintas, que potencialmente pueden dar lugar a la activación de diferentes 
sustratos. En la primera, PKB es fosforilada inicialmente en la T309, después de 
interaccionar con PIP3 en la superficie interna de la membrana celular. En la 
segunda, PKB es fosforilada en primer lugar en la S474 y, por lo tanto, HM 
interactúa preferentemente con el bolsillo hidrofobico PIF de PDK1, promoviendo 
la fosforilación de la T309. 
9. El dominio FERM de FAK puede ser diana para compuestos de pequeño tamaño. 
10. Hemos obtenido resultados estructurales interesantes para dos fragmentos que 
interaccionan con el dominio FERM de FAK a nivel de bolsillos específicos. Se 
podrían diseñar compuestos más afines basándose en la información estructural 
recopilada en este trabajo. 	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